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Celiac disease (CD) is a condition of immunologic intolerance to proteins  
in the common food cereals wheat, rye and barley. CD is primarily a bowel 
disease, as the pathogenic events take place in the small intestinal mucosa 
resulting in inflammation, mucosal atrophy, malabsorption, and finally, 
development of clinical symptoms. The causal relationship between wheat 
gluten proteins and the development of CD was established in the 1940s; since 
then there has been huge progress in understanding the mechanisms of the 
disease pathogenesis. Meanwhile, the disease has changed too – from a 
relatively rare disease of early childhood with classical symptoms of diarrhoea, 
failure to thrive, and abdominal distension, to a widespread condition affecting 
up to 1% of the western population of all ages, and displaying a wide range of 
clinical symptoms. 
The development of CD can be regarded as the loss of immunologic 
tolerance towards gluten proteins in wheat and similar proteins in rye and 
barley. The innate and adaptive immune response against gluten is accompanied 
by autoimmunity against a self protein, transglutaminase 2 (TG2), leading to 
inflammation and tissue lesion in the intestinal mucosa of CD patients. 
Detection of anti-TG2 IgA antibodies from blood sera has become a valuable 
tool for the serologic screening of CD, displaying high diagnostic accuracy. 
However, a few false positive results can still be found when screening for CD 
using anti-TG2 antibodies, prompting the need for further optimization of anti-
TG2 antibody assays. Intestinal biopsy is still required to diagnose CD, but the 
role of accurate antibody assays is highly important for the efficient selection of 
patients for biopsy. In addition, finding new autoantibodies as markers to 
screen, monitor, and prognose disease progression more efficiently remains a 
challenging task for researchers.  
Apart from being a good disease marker, anti-TG2 antibodies could have a 
role in CD pathogenesis. TG2 is expressed in the small intestine, and in patients 
with CD, IgA antibodies co-localise with extracellular TG2 in the intestinal 
mucosa. The transamidase activity of TG2 can modify proteins post-
translationally, which in patients with CD could lead to the modification of 
gluten peptides and enhanced T- and B-cell responses towards gluten  
and TG2 itself. TG2 is also involved in many biological processes like cell 
proliferation, apoptosis, adhesion, endocytosis, and the formation of the 
extracellular matrix (ECM). Therefore, the question arises as to whether 
autoantibodies can affect any of the biological or pathological activities of TG2. 
Previous studies show that anti-TG2 antibodies from CD patients interfere  
with the transamidation activity of TG2, as well as with various cellular 




The aims of this thesis were to identify new autoantibody markers for CD 
and to develop advanced antibody assays for the detection of anti-TG2 
antibodies for CD screening. The thesis also investigated whether anti-TG2 
antibodies could affect the cell adhesion function of TG2 through inhibiting 
TG2 binding to heparan sulphate/heparin molecules. Finally, a preliminary 
identification of the heparin-binding regions of TG2 was undertaken, using 




2. BACKGROUND TO THE STUDY 
2.1. Celiac disease 
Celiac disease, also known as celiac sprue or gluten-sensitive enteropathy, is a 
chronic inflammatory intestinal disease, which is induced by the ingestion of 
proline- and glutamine-rich proteins of wheat (gluten), rye and barley in 
genetically susceptible individuals (Lundin et al. 2005). Samuel Gee first 
described the classical features of CD in 1888 (Gee 1888), but it was not until 
the 1940s that the Dutch paediatrician, Willem-Karel Dicke, established a 
causal relationship between cereal consumption and intestinal symptoms, and 
suggested a gluten-free diet (GFD) as the primary cure for CD (van Berge-
Henegouwen and Mulder 1993). CD was considered to be a condition mainly 
affecting young children when they encountered cereals in their diet. The 
classical disease form is characterized by malabsorbtion syndrome with 
diarrhoea, failure to thrive, and abdominal distension as the main intestinal 
symptoms (Lundin et al. 2005). Nowadays the clinical spectrum of CD is more 
varied, encompassing an increasing number of mild disease forms, extra-
intestinal manifestations and even subclinical cases (Green and Jabri 2003; Di 
Sabatino and Corazza 2009). Also the disease can be found and diagnosed in all 
age groups (Volta and Villanacci 2011). 
Villous atrophy and crypt hyperplasia of the intestinal mucosa in the upper-
middle part of the jejunum are the histological hallmarks of CD. Marsh (1992), 
graded the extent of tissue alterations from intraepithelial lymphocytosis to 
partial, subtotal, and total villous atrophy; minor intestinal changes, like 
intraepithelial lymphocytosis, are less specific for CD (Volta and Villanacci 
2011). The small intestinal biopsy with a characteristic CD histology has 
remained a gold standard for CD diagnosis, along with clinical or histological 
improvement after a period on a gluten-free diet (Walker-Smith et al. 1990). 
The strong association of CD with certain class II human leukocyte antigen 
(HLA) haplotypes and the presence of serum antibodies against TG2 as reliable 
disease markers, has led to growing support for undertaking CD diagnosis 
without performing a biopsy in a subgroup of patients with high autoantibody 
levels (Volta and Villanacci 2011; Husby et al. 2012). 
CD occurs mainly in countries where the disease inducing cereals are 
consumed – that is all over the world except for parts of Asia and Africa. The 
highest prevalence is in Europe where CD affects up to 1% of the population 
(Dubé et al. 2005; Mustalahti et al. 2010). The prevalence of CD does vary 
significantly between countries, as from 0.3% in Germany to over 1% preva-
lence in Sweden and Finland (Mäki et al. 2003; Mustalahti et al. 2010; Walker 
et al. 2010). The incidence and prevalence of CD has been increasing for some 
decades; the wide use of serologic assays for CD screening and an increased 
awareness among physicians have been suggested as the main reasons for this 
(Green and Jabri 2003; Di Sabatino and Corazza 2009). On the other hand, the 
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incidence of many allergic and autoimmune diseases has increased in developed 
countries as a consequence of changing environments and lifestyles (Borchers et 
al. 2010). For example, the incidence of CD among children increased tenfold 
in Estonia, to 1 per 2,700 live births in a year, after clinical screening in 1990–
1994, whereas no CD cases were found by screening for antibodies in general 
population (Uibo et al. 1996). Ten years later, after a profound socioeconomic 
change in the country, the serological screening for CD among schoolchildren 
revealed a disease prevalence of 0.34% in Estonia (Ress et al. 2007).    
CD is associated with several, mainly autoimmune diseases, which also 
comprise potential risk groups for CD screening. The prevalence of CD is 
higher than in the general population among patients with IgA deficiency 
(Collin et al. 1992), type 1 diabetes (Holmes 2001), autoimmune thyreoiditis 
(Sategna-Guidetti et al. 1998), autoimmune hepatitis (Volta et al. 1998), 
Down’s syndrome (George et al. 1996), Turner syndrome (Ivarsson et al. 1999) 
and in some other conditions (Volta and Villanacci 2011).  
Dermatitis herpetiformis (DH), a blistering skin disease with IgA deposits in 
the dermis, is considered to be a skin manifestation of gluten enteropathy, as 
almost all patients have intestinal lesions and antibody markers characteristic of 
CD (Sárdy et al. 2002). Refractory sprue or refractory CD is a rare CD-related 
condition with a poor prognosis, not responsive to the GFD, and leading fre-
quently to development of T-cell lymphoma (Cellier et al. 2000). The risk of 
lymphoproliferative malignancies is also higher for untreated CD (Di Sabatino 
and Corazza 2009). Furthermore, the overall mortality rate for symptomatic CD 
is increased, but varies in different studies, and is found to be associated with 
the level of gluten consumption in the population (Biagi and Corazza 2010). A 
gluten-free diet remains the only approved and effective therapy for CD, but 
many initiatives are being undertaken to develop novel therapies for CD, 
directed at modifying the immunogenic potential of gluten or the immune 
response to it (Schuppan et al. 2009). 
 
 
2.2. Immunopathogenesis of CD 
2.2.1. Environmental triggers 
The early observations in 1940s, that wheat consumption is harmful to celiac 
patients, have initiated the sudies in the following decades to explore the disease 
inducing role of wheat gluten and homologous proteins in rye and barley 
(Heyman et al. 2011). Although the mechanisms of CD pathogenesis have been 
described at molecular and cellular level, the primary events leading to disease 
development in the genetically predisposed subjects still remain unknown. 
Gluten consists of water-insoluble storage proteins of wheat grains, which 
can be separated to alcohol-soluble and non-soluble gliadin and glutenin 
fractions, respectively (Wieser 1995). Both fractions contain many closely 
related proteins, altogether coded by at least 100 genes, and characterized by a 
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high content of glutamine (approximately 35 mol%), proline (15 mol%), and 
hydrophobic amino acids (19 mol%). Prolamin is a common term for alcohol-
soluble proteins in cereals, including proteins similar to gliadin in rye (secalin), 
barley (hordein), and oats (avenin). Based on sequence similarity and their 
biochemical properties, gliadin proteins are divided into α-, - and -gliadins 
(Wieser 1995). 
The gliadin fraction, especially α-gliadin, is regarded as the most potent 
gluten component to induce CD, retaining its toxicity after digestion with 
pepsin and trypsin (Heyman et al. 2011). Although initially hypothesized, no 
inherited inability to degrade gliadin proteins by digestive enzymes in gut 
lumen has been found in CD (Matysiak-Budnik et al. 2003). However, the 
relative resistance of gliadin proteins to hydrolysis by intestinal proteases and 
peptidases, compared with other food proteins, has been established as a factor 
for increased immunogenicity (Hausch et al. 2002). Based on numerous in vivo 
and ex vivo studies, and also using intestinal biopsies from CD patients in 
culture, gliadin toxicity for CD has been mostly confined to α-gliadin amino 
acid sequences 31–55 and 57–89 (de Ritis et al. 1988; Wieser 1995; Shan et al. 
2002). The immune response against gliadin is considered to be the crucial 
event in the immunopathogenesis of CD (Jabri and Sollid 2006). Also the direct 
effects of gliadin, especially α-gliadin peptide 31–55, on intestinal epithelial 
cells have been described in cellular model systems. Gliadin peptides increase 
cellular oxidative stress (Rivabene et al. 1999; Luciani et al. 2010) and the rate 
of apoptosis (Giovannini et al. 2000), induce actin cytoskeleton rearrangements 
(Clemente et al. 2003), and exhibit growth factor-like activity on intestinal 
epithelial cells (Barone et al. 2007b). The binding of the gliadin peptides to the 
chemokine receptor, CXCR3, with the subsequent release of zonulin, a 
regulatory protein of enterocyte tight junctions, and an increase in intestinal 
permeability, has been reported (Lammers et al. 2008). 
The transport of gliadin peptides into the lamina propria of small intestinal 
mucosa occurs both by paracellular and transcellular pathways in CD (Heyman 
et al. 2011). Paracellular permeability is controlled by tight junctions between 
intestinal epithelial cells which are permeable to ions and small molecules in 
normal conditions. The intestinal barrier function is impaired in active CD and 
this can be mediated by the direct gliadin effect on the intestinal epithelium 
(Sander et al. 2005), or by ongoing inflammation with interferon (IFN)- pro-
duction in the lamina propria (Schumann et al. 2008). The transcellular passage 
of non-degraded gliadin peptides is also increased in the small intestinal mucosa 
of CD patients (Schumann et al. 2008), and in a macaque model of CD 
(Bethune et al. 2008). An abnormal retrotransport of gliadin-IgA complexes by 
the CD71 receptor on the apical part of enterocytes has been suggested as an 
additional mechanism promoting gliadin translocation to the lamina propria of 
intestinal mucosa in CD patients (Matysiak-Budnik et al. 2008). 
Intestinal infections are considered to be additional factors for gluten 
intolerance in CD, but only limited data are available to support this hypothesis 
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(Forsberg et al. 2004). An epidemiological study found that rotavirus infection 
increased the risk of CD in genetically predisposed children (Stene et al. 2006). 
 
 
2.2.2. Genetic susceptibility 
CD has strong familial clustering, indicated by a disease concordance rate of 
75% in monozygotic twins, compared with 11% in dizygotic twins (Greco et al. 
2002). The major genetic determinants of CD are class II HLA genes encoding 
the HLA-DQ2 heterodimer in more than 90% of CD patients and the DQ8 
heterodimer in most of the remaining CD patients (Sollid et al. 1989; Spurkland 
et al. 1992). The alleles HLA-DQA1*05 and HLA-DQB1*02, encoding for 
HLA-DQ2 α and β subunits, are carried either by a DR3 haplotype in the cis 
position or by DR5/DR7 haplotypes in the trans position, with a gene dosage 
effect on CD risk (Sollid et al. 1989; Ploski et al. 1993). However, the 
expression of HLA-DQ2 or HLA-DQ8 molecules is necessary but insufficient 
to develop CD, since the corresponding HLA haplotypes occur in about 30% of 
the European population, indicating the involvement of other genes in CD 
heritability (Dubois and van Heel 2008). Linkage and association studies have 
revealed some additional candidate chromosomal regions and genes to be 
associated with CD (Djilali-Saiah et al. 1998; Greco et al. 1998). The recent 
application of genome-wide association studies has led to the identification of a 
number of new CD common variant risk loci with more candidate genes (van 
Heel et al. 2007; Hunt et al. 2008; Dubois et al. 2010; Trynka et al. 2011). 
Twenty eight of the 39 non-HLA susceptibility loci for CD identified so far 
were found to be related to the genes of the immune system involving pathways 
of immune cell signalling, T- and B-cell differentiation, and innate immunity. 
Moreover, 26 CD genetic risk regions are also associated with other auto-
immune and inflammatory conditions, suggesting a role for common pathways 
in the immunopathology of these diseases (Trynka et al. 2010). The individual 
risk values of associated loci are moderate for CD (highest odds ratio 1.7), and 
the current set of non-HLA genetic markers has been estimated to describe 
about 14% of the genetic variability of CD, compared with a contribution of 
about 40% of HLA-DQ (Trynka et al. 2011). 
 
 
2.2.3. Adaptive immune response 
The isolation and characterization of gluten-specific HLA-DQ2 restricted CD4+ 
T-cells from the intestinal mucosa of CD patients has established a causal link 
between HLA association and the induction of a gluten-specific T-cell response 
as an essential disease mechanism in CD (Lundin et al. 1993). The following 
studies have dissected the nature of gluten peptides presented by HLA-DQ2 and 




The deamidation of certain glutamine residues to glutamate in gliadin 
peptides by TG2, a CD autoantigen, has been found to enhance the gliadin-
specific CD4+ T-cell response in CD (Molberg et al. 1998), substantiated by the 
higher affinity of modified peptides for binding to disease-associated HLA-DQ 
molecules (Sjöström et al. 1998; Arentz-Hansen et al. 2000). Subsequent 
studies identify immunodominant, TG2-dependent or -independent epitopes in 
- and -gliadins and glutenins (van de Wal et al. 1998; Anderson et al. 2000; 
Arentz-Hansen et al. 2000; Tollefsen et al. 2006). A 33 amino acid long peptide 
(33-mer) resistant to intestinal proteases was identified in an α2-gliadin 
sequence (amino acids 57–89), inducing potent T-cell responses in all studied 
CD patients, and thus forming the structural basis for gluten intolerance in CD 
(Shan et al. 2002). The 33-mer peptide contains multiple immunodominant 
epitopes of α-gliadins, and is similar to the sequences in other gliadins as well 
as in hordeins and secalins (Shan et al. 2002; Shan et al. 2005). There is also 
some evidence of the presence of gliadin-specific CD8+ T-cells restricted to 
HLA-A2 in the small intestinal mucosa of CD patients (Gianfrani et al. 2003; 
Mazzarella et al. 2008).  
Gluten-specific CD4+ T-cells from the intestinal biopsies of CD patients are 
producing cytokines characteristic of type 1 helper T-cells or of mixed type 
response with predominant production of IFN- (Nilsen et al. 1995) and IL-21 
(Bodd et al. 2010), which are also increased at the tissue level (Nilsen et al. 
1995; Fina et al. 2008). Research suggests that helper T-cell differentiation in 
the small intestinal mucosa of CD patients is promoted by overproduction of 
IFN-α, IL-18, and IL-21 (Monteleone et al. 2001; Salvati et al. 2002; Fina et al. 
2008). Also IL-17A producing T-cells have been found in CD (Castellanos-
Rubio et al. 2009; Monteleone et al. 2010), but their specificity, and the actual 
increase of IL-17A in the CD lesion are not yet clear (Bodd et al. 2010). The 
pathogenic T-cell response in CD is accompanied by a relative increase of 
regulatory T-cells in the intestinal mucosa, both of IL-10 producing T-cells 
(Gianfrani et al. 2006), and FoxP3+/CD25+ T-cells (Tiittanen et al. 2008; 
Vorobjova et al. 2009), although the ability of FoxP3+/CD25+ T-cells to 
suppress effector T-cell proliferation and IFN- production is impaired in CD by 
an IL-15 dependent mechanism (Zanzi et al. 2011; Hmida et al. 2011). IFN- 
and other proinflammatory cytokines, produced by gluten-specific T-helper 
cells, have direct pathogenic effects on the intestinal epithelial cells as well 
indirect effects on other immune cells for promoting inflammation in the 
intestinal mucosa (Przemioslo et al. 1995; Jabri and Sollid 2009). 
The number of plasma cells in the lamina propria of CD patients’ small 
intestinal mucosa is higher than in healthy people, consisting mainly of IgA+ 
plasma cells of both IgA1 and IgA2 subclasses in about equal amounts 
(Savilahti 1972; Kett et al. 1990). Approximately 5–10% of intestinal plasma 
cells are estimated to produce anti-gliadin antibodies with a predominance of 
the IgA class (Lycke et al. 1989; Brandtzaeg 2006). Still, the pathogenic 
potential of IgG antibodies, especially of IgG1 subclass, has been considered 
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higher due to complement activation and other proinflammatory effector 
functions (Brandtzaeg 2006). High concentrations of secreted IgA and IgM anti-
gliadin antibodies have been detected in the jejunal fluid of untreated CD 
patients (Volta et al. 1988). Moreover, intestinal IgA/IgM antibodies against 
gliadin and TG2 appear in CD patients before the development of small 
intestinal atrophy (O’Mahony et al. 1990; Salmi et al. 2006b), reflecting early 
homeostatic immune activation (Brandtzaeg 2006). Also, the majority of serum 
IgA antibodies against gliadin and TG2 have been suggested to have mucosal 
origins (Brandtzaeg 2006; Kett et al. 1990).   
 
 
2.2.4. Innate immune response 
Studies over the last decade have shown that both innate and adaptive types of 
immunity are necessary to induce the cascade of immunopathogenic events that 
lead to CD in subjects with genetic susceptibility (Jabri and Sollid 2006). In 
Figure 1, the major immunopathogenetic mechanisms of CD are presented.  
By testing gliadin peptides on ex vivo intestinal biopsies from CD patients, 
early immune activation with increased IL-15 production and enterocyte 
apoptosis was observed with α-gliadin peptide 31–43, but not with CD4+ T-cell 
immunodominant gliadin peptides (Maiuri et al. 2003). The number of 
intraepithelial lymphocytes (IEL), consisting mainly of T-cell receptor (TCR) 
αβ bearing CD8+ T-cells with some TCR+ , mainly CD8– T-cells, is known 
to be increased in CD (Halstensen et al. 1989; Kutlu et al. 1993). TCRαβ+ IELs 
are correlated with gluten consumption and the degree of villous atrophy and 
their cytolytic activity has been related to enterocyte damage in CD (Kutlu et al. 
1993; Ciccocioppo et al. 2000). Increased production of IL-15 in the intestinal 
mucosa of CD patients (Maiuri et al. 2000; Mention et al. 2003) is considered 
crucial to differentiate IELs into natural killer (NK)-cell type phenotype of 
CD8+ IEL with expression of NKG2D and other activating receptors (Hüe et al. 
2004; Meresse et al. 2004; Meresse et al. 2006). Simultaneously, stressed 
intestinal epithelial cells are expressing the non-classical HLA class I receptor 
MICA as a ligand for NKG2D, leading to the destruction of enterocytes by IELs 
independently of TCR engagement (Hüe et al. 2004; Meresse et al. 2004). 
Furthermore, IL-15 and other cytokines delivered by stressed enterocytes and 
activated IELs could change tolerogenic dendritic cells into an inflammatory 
type, and thereby promote a DQ2/DQ8 dependent gliadin-specific T-cell 
response in the small intestinal mucosa (Jabri and Sollid 2009). Activated IELs 
also produce arachidonic acid and leukotrienes, which could promote local 
inflammation and recruitment of granulocytes into the lesion (Tang et al. 2009). 
However, the mechanisms by which gliadin and possible other factors induce 
intestinal epithelial cell stress, IL-15 production, and loss of tolerance to gluten 
in CD, have still not been resolved (Jabri and Sollid 2009). 
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Figure 1. The model of CD immunopathogenesis in the small intestinal mucosa. 
Gliadin peptides in the gut lumen enter lamina propria of intestinal mucosa through both 
the transcellular and paracelluar pathways. Peptides corresponding to α-gliadin amino 
acid sequence 57–89 trigger the CD4+ T-cell response when presented in the complex 
with HLA-DQ2 or -DQ8 molecules by dendritic cells (DC). TG2 converts glutamine 
(Q) residues in native gliadin peptides to glutamate (E), resulting in a more vigorous T-
cell response. Activated gliadin-specific T-helper cells produce cytokines (IFN-γ, IL-
21) and provide help to B-cells for producing antibodies against gliadin and TG2. Innate 
immune mechanisms are activated by the effects of α-gliadin amino acid sequence 31–
49, leading to IL-15 production by enterocytes and subsequent licensing of 
intraepithelial lymphocytes (IEL) to lyse enterocytes through engagement of 
NKG2D/MIC receptor system. TCR, T-cell receptor; NKG2D, natural killer group 2 
member D; MICA, major histocombatibility complex class I-related chain A.  
 
 
2.3. Transglutaminase 2 
 
2.3.1. Structure and biological functions 
Transglutaminase 2 (TG2; tissue transglutaminase, transglutaminase C) belongs 
to the transglutaminase protein family encoded by eight genes in the human 
genome. The common feature of all transglutaminases is their ability to catalyze 
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the post-translational modification of proteins either by forming N-(-glutamyl) 
lysine isopeptide bonds between certain glutamine and lysine side chains, 
incorporating polyamines into proteins, or by deamidating glutamine residues to 
glutamate in the absence of amine donors (Lorand and Graham 2003). Com-
pared to other transglutaminases expressed in the limited tissues or cell types, 
TG2 is expressed ubiquitously in tissues and it is carrying diverse functions in 
multicellular organisms. TG2 is involved in the cellular processes of apoptosis, 
endocytosis, signal transduction, adhesion, and extracellular matrix formation 
(Griffin et al. 2002; Iismaa et al. 2009). Apart from its Ca2+-dependent 
transamidation activity, TG2 binds GTP/GDP and acts as a GTPase in 
intracellular G protein signalling (Nakaoka et al. 1994). The protein disulfide 
isomerase (Hasegawa et al. 2003) and serin/threonin kinase (Mishra and 
Murphy 2004) activities of TG2 have also been described, although they have 
been studied less. 
TG2 is encoded by the TGM2 gene on the human chromosome 20q11–12 
and contains 687 amino acid residues in a polypeptide chain with a molecular 
weight of 77 kDa. Human TG2 consists of four protein domains characteristic 
of all transglutaminases: N-terminal -sandwich domain (amino acids 1–139), 
catalytic or core domain with mainly -helical secondary structure (147–460), 
and two C-terminal -barrel domains (472–583 and 591–687) (Liu et al. 2002). 
A schematic representation of the molecular structure of TG2 and its domain 
composition are shown in Figure 2. The loop between the catalytic domain and 
the first -barrel domain acts as a hinge region to enable the switch between two 
conformational states of TG2: an “open” conformation with transamidation 
activity (Pinkas et al. 2007) and a “closed” conformation with GTPase activity 
(Liu et al. 2002). These two conformational states are reciprocally regulated by 
binding Ca2+ ions or GTP/GDP, respectively, and stabilized by intracellular 
disulphide bonds between cysteine residues (Cys-230, Cys-370, Cys-371) 
(Pinkas et al. 2007; Han et al. 2010). The catalytic site in the open conformation 
of TG2 is accessible for binding first with acyl-donor and then with acyl-
acceptor substrates for transamidation, and the catalytic triad residues of Cys-
277, His-355,Asp-358 are critical in this reaction (Liu et al. 2002; Pinkas et al. 
2007). 
TG2 expression at the transcriptional level can be up-regulated by cytokines 
(TGF-, TNF-, IL-1 and IL-6), retinoids, vitamin D, and steroid hormones 
(Mehta et al. 2010). TGF- and retinoid response elements are located in the 
promotor region of the TGM2 gene (Ritter and Davies 1998). Intracellular TG2 
is normally in the “closed” conformation, due to low Ca2+ and high GTP 
concentrations being the main regulators of TG2 activity (Monsonego et al. 
1998; Zhang et al. 1998). Various stress stimuli, accompanied by the increase of 
intracellular Ca2+ levels, can switch on the transamidation activity of TG2 





Figure 2. Schematic representation of the molecular and domain structure of TG2. (A) 
The GDP-bound form of TG2, representing the “closed” conformation with no 
transamidase activity (Liu et al. 2002; PDB code: 1KV3). (B) Extended, the “open” 
conformation of TG2 with transamidase activity (Pinkas et al. 2007; PDB code: 2Q3Z). 
A substrate binding site in the catalytic domain of TG2 is opened by a large Ca2+-
dependent conformational change. (C) The domain structure of TG2 and the main 
functional and binding sites. 
 
 
apoptotic process. Both the pro- and anti-apoptotic effects of TG2 have been 
described, and the types of apoptotic stimuli, and the intracellular localization of 
TG2 are perceived as important determinants of its effect on apoptosis 
(Milakovic et al. 2004; Fésüs and Szondy 2005). The majority of intracellular 
TG2 is expressed in the cytosol, but TG2 is also found in the nucleus (Lesort et 
al. 1998) and in the mitochondria (Park et al. 2010). The stabilizing role of TG2 
by cross-linking intracellular proteins in the later stages of apoptosis has been 
suggested to prevent the loss of intracellular components prior to clearance by 
phagocytosis (Piredda et al. 1997; Piacentini and Colizzi 1999). Studies on TG2 
knock-out mice have revealed that despite the overt normal foetal phenotype, 
lack of TG2 affects clearance of dying cells by macrophages, and mice develop 
age-dependent autoimmunity (Szondy et al. 2003; Rose et al. 2006). A signi-
ficant number of intra- and extracellular substrate proteins of TG2 have been 
identified by proteomic methods in vitro and in vivo, and the physiological 
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relevance of some of these post-translational modifications has been explored 
(Esposito and Caputo 2005). Transamidation of proteins by TG2 typically leads 
to the formation of cross-linked, polymerized protein scaffolds with altered 
functional properties (Griffin et al. 2002). 
 
 
2.3.2. TG2 and cell adhesion 
Although primarily considered as an intracellular protein, TG2 is also expressed 
on the cell surface and in the ECM (Zemskov et al. 2006; Belkin 2011; Wang 
and Griffin 2012). The mechanism of TG2 transport to the plasma membrane 
and secretion to the ECM is largely unknown, as TG2 has no leader peptide for 
externalization (Belkin 2011). Even though the Ca2+ concentration is higher in 
the extracellular space, the extracellular TG2 is catalytically inactive in normal 
physiological conditions, but can be rapidly activated after chemical or physical 
injury (Siegel et al. 2008). Cross-linking of extracellular proteins by TG2 is 
functionally related to the stabilization of ECM in normal tissue modelling as 
well as in the response to injury as it occurs in wound healing (Zemskov et al. 
2006). 
Independent of its transamidase activity, TG2 is also involved in the cell 
adhesion process through interactions with proteins of the cell membrane and 
ECM (Akimov et al. 2000; Verderio et al. 2003). The role of TG2 in cell 
adhesion is related to its high affinity binding to fibronectin (FN), a multi-
functional ECM protein (Gaudry et al. 1999; Hang et al. 2005). FN is a high 
molecular weight modular glycoprotein, forming a homodimer of 440 kDa. FN 
promotes cell adhesion in its polymerized form and serves as a scaffold for the 
assembly of other ECM molecules (Zemskov et al. 2006). The FN binding 
region of TG2 is in the N-terminal domain (amino acids 88–106), and two TG2 
molecules bind to the FN homodimer (Hang et al. 2005). Cell surface TG2 is 
involved in FN polymerization and is closely associated with the FN fibrillar 
matrix (Verderio et al. 1998; Akimov and Belkin 2001a). A complex formation 
between FN, TG2 and cell surface integrins promotes cell adhesion and spreading 
(Akimov et al. 2000; Belkin 2011). Integrins can directly bind to FN by 
recognizing the Arg-Gly-Asp (RGD) sequence containing sites within the type III 
domain of FN (Pierschbacher and Ruoslahti 1984) or by interacting via 1/3/5 
subunits, with TG2 as a co-receptor for FN (Akimov et al. 2000). Both FN and 
TG2 can also interact with the heparan sulphate (HS) residues of the cell surface 
proteoglycans, and through this, support RGD-independent cell adhesion 
(Verderio et al. 2003; Telci et al. 2008). Syndecan-4 is thought to be the main 
TG2-binding heparan sulphate proteoglycan (HSPG) on the cell surface (Telci 
et al. 2008; Scarpellini et al. 2009). A model has been proposed in which the 
FN-TG2 matrix promotes cell adhesion via interactions with syndecan-4 and 
integrin 51, leading to the activation of protein kinase C- and focal adhesion 
kinase (Telci et al. 2008; Verderio et al. 2009; Wang et al. 2010). 
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HSPGs are composed of a core protein and one or more linear polysaccha-
ride chains, consisting of sulphated L-iduronic /D-glucuronic acid and gluco-
samine units. HSPGs are involved in processes of cellular communication by 
binding a variety of protein ligands like ECM proteins, growth factors, 
chemokines and cytokines (Bishop et al. 2007). Structurally HS is very close to 
heparin, which is widely used as a model to study protein-HS interactions. The 
mechanism of protein and heparin/HS binding is based on the electrostatic 
interactions between negatively charged residues of heparin/HS and positively 
charged basic amino acid residues of arginine and lysine in polypeptide chains. 
Most of the heparin/HS binding sites in proteins contain clusters of basic amino 
acids, and two common heparin binding consensus sequences have been 
proposed (XBBBXXBX and XBBXBX; B-basic, X-non basic amino acids) 
(Cardin and Weintraub 1989).  
The binding of TG2 to heparin is known about from earlier studies and this 
feature was exploited for the affinity purification of TG2 on the heparin-
Sepharose matrix (Signorini et al. 1988). Scarpellini et al. (2009), demonstrate 
high-affinity binding of guinea pig TG2 (gpTG2) to heparin and HS by the 
surface plasmon resonance (SPR) method. 
 
 
2.3.3. TG2 in CD 
TG2 is involved in a variety of pathologic conditions including celiac disease 
(Molberg et al. 2000), neurodegenerative disorders (Kim et al. 2002), fibrotic 
diseases (Wu and Zern 2004), and cancer (Mehta et al. 2010). While the expres-
sion and activity of TG2 are primarily regulated by stress signals, its involve-
ment in chronic inflammatory diseases can be viewed as part of the stress/ 
inflammatory response (Iismaa et al. 2009). In the inflammatory environment, 
TG2 may protect cells from death, promote their motility and advance the 
clearance of apoptotic cells by macrophages (Mehta et al. 2010; Szondy et al. 
2003). However, TG2 can also enhance the inflammatory process by activating 
NF-B via non-canonical pathways (Lee et al. 2004; Luciani et al. 2009). High 
transamidase activity of TG2 is involved in forming pathogenic, cross-linked 
protein aggregates in Alzheimer’s, Huntington’s, and Parkinson’s diseases (Kim 
et al. 2002). The changed antigenic properties of proteins modified by TG2 could 
induce autoimmunity in inflammatory conditions. This hypothesis is indirectly 
supported by the notion that TG2 substrate proteins often are known autoantigens 
in various autoimmune diseases (Kim et al. 2002). The relevance of TG2 for 
carcinogenesis depends on the type and stage of cancer as well on the localization 
and functional state of the TG2. Typically, TG2 is down-regulated in primary 
tumours, whereas TG2 expression is elevated in secondary, metastatic tumours 
where TG2 is implicated in promoting the invasive potential of the cells and 
conferring resistance to chemotherapeutic drugs (Kotsakis and Griffin 2007; 
Mehta et al. 2010). TG2 is considered to be a promising therapeutic target for 
treating drug-resistant and metastatic tumours (Mehta et al. 2010). 
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TG2 came to the attention of CD researchers after Dieterich and colleagues 
identified it as the main autoantigen for anti-endomysium IgA antibodies 
(EmA-IgA) (Dieterich et al. 1997). Increased transglutaminase activity in the 
jejunal biopsies of CD patients, with gliadin as the preferential substrate among 
dietary proteins, has been described earlier (Bruce et al. 1985). The higher 
expression of TG2 in the small intestinal mucosa of CD patients has since been 
revealed both at the mRNA and protein level (Ciccocioppo et al. 2003; Esposito 
et al. 2003; Biagi et al. 2006). TG2 is present in the lamina muscularis and to a 
lesser extent in the lamina propria of the normal small intestinal mucosa 
(Esposito et al. 2003; Sakly et al. 2005). The expression of TG2 is more 
pronounced in the subepithelial region of lamina propria in the atrophic small 
intestinal mucosa of CD patients (Esposito et al. 2003; Sakly et al. 2005; 
Gorgun et al. 2009), and in the enterocytes (Esposito et al. 2003; Biagi et al. 
2006; Gorgun et al. 2009). However, some studies have found no difference in 
intestinal TG2 expression and activity between children with and without CD 
(Skovbjerg et al. 2004a), or between different stages of the disease (Villanacci 
et al. 2009). What is more an increase in TG2 expression does not seem to be 
disease specific, as similar upregulation of TG2 was detected in other 
inflammatory conditions of the small intestine (Esposito et al. 2003; Gorgun et 
al. 2009; Villanacci et al. 2009). 
The crucial role of TG2 in CD immunopathogenesis was revealed by the 
finding that TG2 enhances the gliadin-specific CD4+ T-cell response by deami-
dating certain glutamine residues to glutamate in gliadin peptides (Molberg et 
al. 1998). TG2 could also mediate the formation of covalently linked gliadin-
gliadin and gliadin-TG2 complexes in vitro (Dieterich et al. 1997; Uhlig et al. 
1998; Fleckenstein et al. 2004; Dieterich et al. 2006). Sollid et al. (1997) 
suggested that TG2-specific B-cells, by processing and presenting TG2 cross-
linked with gliadin, could get help from gliadin-specific T-cells to produce 
autoantibodies against TG2. Furthermore, via such a hapten-carrier model, 
autoantibodies could be induced towards other autoantigens complexed with 
gliadin (Sollid et al. 1997; Uhlig et al. 1998; Molberg et al. 2000; Skovbjerg et 
al. 2004b). In vitro studies have demonstrated cross-linking of gliadin peptides 
with collagens by TG2, and elevated serum IgA antibodies against these 
proteins were found in CD patients (Dieterich et al. 2006). Deamidation or 
transamidation of gliadin peptides and other substrate proteins is believed to be 
catalyzed by extracellular TG2, localized below the intestinal epithelial cell 
layer in a CD lesion (Fleckenstein et al. 2002; Ciccocioppo et al. 2003; 
Skovbjerg et al. 2004b; Siegel et al. 2008; Skovbjerg et al. 2008). The potential 
role of TG2 on the surface of intestinal dendritic cells in deamidation and 
presentation of gluten peptides to T-cells has been explored but no evidence was 






2.4. Antibodies in CD 
2.4.1. Anti-gliadin antibodies 
Berger (1958), first described antibodies against gluten proteins in the blood 
sera of CD patients, and this was followed by the development of various 
methods for the detection of anti-gliadin antibodies (AGA) from human sera 
(Bürgin-Wolff et al. 1976; O’Farrelly et al. 1983). IgA and IgG class AGA 
were found to be useful serologic markers for CD screening and monitoring the 
adherence to a gluten free diet, as antibody levels were dependent on gluten 
consumption in CD patients (Savilahti et al. 1983; Bürgin-Wolff et al. 1991; 
Mäki 1995). The diagnostic accuracy was higher for AGA-IgA, reaching over 
90% of sensitivity and specificity, and lower for AGA-IgG, which was also 
detected in other diseases and in healthy subjects (Mäki 1995). AGA was found 
to be a more accurate CD diagnostic marker for children than for adults (Mäki 
1995), and this was also supported by the finding that AGA-IgA positivity 
increases with age in the general population (Uibo et al. 1993). The new era of 
AGA as a biomarker for CD came after the identification of gliadin peptide 
epitopes, where certain glutamine residues were replaced with glutamate, 
providing an antigen for more accurate CD screening tests (Schwertz et al. 
2004). Anti-deamidated gliadin antibody (AdGA) IgA and IgG assays showed 
equally high sensitivity and specificity for CD, and are suggested as valuable 
serologic markers for CD screening in combination with anti-TG2 antibodies 
(Sugai et al. 2006; Agardh 2007; Volta et al. 2008). 
 
 
2.4.2. Anti-reticulin and anti-endomysium antibodies 
The first study on CD-associated serum autoantibodies, which bind to auto-
logous or homologous jejunal mucosa, was published by Malik and colleagues 
(Malik et al. 1964). This was followed by a description of specific IgG and IgA 
class autoantibody staining patterns on rodent tissue sections – called anti-
reticulin antibodies (ARA) (Seah et al. 1971a; Seah et al. 1971b), and on pri-
mate oesophagus tissue sections – called anti-endomysium antibodies (EmA) 
(Chorzelski et al. 1983). Both autoantibodies were found in sera of CD patients 
when studied by the indirect immunofluorescence (IIF) technique. As an 
advance in assay optimization, human umbilical cord was used as a suitable 
antigenic substrate for detection of IgA class EmA (Ladinser et al. 1994), 
becoming a highly specific (97–100%) and sensitive (71–100%) serologic 
marker for CD (Lewis and Scott 2006). A somewhat lower prevalence of  
EmA-IgA was observed in children under the age of two (Grodzinsky et al. 
1995) and in adults with CD (Sulkanen et al. 1998a).  
EmA-IgA binds to the connective tissue surrounding smooth muscle and 
stromal cells and produces a staining pattern clearly distinctive from other 
known autoantibodies. ARA and EmA were thought to be close antibody 
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subtypes, detected on tissues of different types and from different species 
(Hällström 1989). Both antibodies appeared to be gluten-dependent – the 
antibody titers decreased or antibodies disappeared in response to a GFD lasting 
for several months and were induced again after introducing gluten to the diet 
(Hällström 1989; Bürgin-Wolff et al. 1991). Moreover, EmA was produced in 
small intestine biopsy samples of CD patients after in vitro gliadin challenge 
(Picarelli et al. 1996). The association of EmA-IgA with small intestinal lesion 
was less clear as, after starting a GFD, antibodies tended to disappear before 
complete mucosal recovery (Dickey et al. 2000).  
Several attempts were made to identify EmA antigens (Marttinen and Mäki 
1993; Börner et al. 1996), until Dieterich and colleagues identified TG2 as the 
main, if not the only EmA antigen (Dieterich et al. 1997). They used immuno-
precipitation of the fibrosarcoma cell lysate with serum IgA antibodies from CD 
patients, followed by the identification of precipitated proteins – TG2 and 
associated FN, using proteomic methods. TG2 was conclusively confirmed to 
be a target antigen of both EmA and ARA in CD and dermatitis herpetiformis 
patients in further studies, and anti-TG2 autoantibodies were found to recognise 
extracellular TG2 in normal rodent and primate tissue (Korponay-Szabó et al. 
2000; Korponay-Szabó et al. 2003b).       
 
 
2.4.3. Anti-TG2 antibodies 
The discovery of TG2 as the primary autoantigen for CD-associated auto-
antibodies led to the development of anti-TG2 antibody assays, both in the 
ELISA format (Dieterich et al. 1998; Sulkanen et al. 1998b), and by using 
immunoprecipitation of in vitro transcribed TG2 (Bazzigaluppi et al. 1999). 
Commercially available gpTG2 was used at first as the antigen in the anti-TG2 
ELISA, and then replaced by human recombinant TG2 (hrTG2), resulting in the 
higher diagnostic accuracy of the assay for CD (Sárdy et al. 1999; Sblattero et 
al. 2000). The diagnostic sensitivity (93%) and specificity (> 98%) of those 
second generation anti-TG2 assays were in the same range as the EmA-IgA test 
(sensitivity 93%, specificity > 99%), based on a large meta-analysis, suggesting 
anti-TG2 IgA as the preferred serologic marker for CD screening (Lewis and 
Scott 2006).  
Anti-TG2 antibodies of the IgG class are detected less frequently among CD 
patients, but have been found to be useful for recognizing CD patients with 
IgA-deficiency (Cataldo et al. 2000; Korponay-Szabó et al. 2003a). There are 
only a few studies where anti-TG2 IgM has been examined in CD, and the 
findings show low antibody prevalence (Agardh et al. 2003; Feighery et al. 
2003). The combined assessment of anti-TG2 IgA and IgG is advised for sero-
logic screening of CD because of the increased diagnostic accuracy (Picarelli et 
al. 2001; Dahlbom et al. 2008). The occurrence of anti-TG2 antibodies but not 
EmA, have been reported in a small proportion of patients with hepatic diseases 
(Bizzaro et al. 2003; Vecchi et al. 2003; Villalta et al. 2005), heart diseases 
28 
(Di Tola et al. 2008), and other autoimmune diseases (Sárdy et al. 2007), 
without having a CD diagnosis. These results are mostly regarded as analytical 
false-positives rather than true anti-TG2 antibodies, prompting the need for 
further assay optimization (Villalta et al. 2005; Sárdy et al. 2007). 
A common feature of solid-phase anti-TG2 antibody assays is the inclusion 
of Ca2+ ions when coating the plate surface with the TG2 antigen, resulting in 
better diagnostic accuracy (Sulkanen et al. 1998b; Agardh et al. 2005). This is 
explained by the “open” conformational structure of TG2 in the presence of 
Ca2+, which is preferentially recognized by CD anti-TG2 antibodies (Lindfors et 
al. 2011). In order to broaden the methodical range of anti-TG2 assessment, 
point-of-care anti-TG2 antibody rapid assays have been developed, comparable 
sensitivity and specificity of ELISA for CD screening (Sorell et al. 2002; 
Korponay-Szabó et al. 2005; Raivio et al. 2006; Baviera et al. 2007). Intere-
stingly, one lateral flow immunochromatographic assay is based on the 
principle of autoantibody binding to self-TG2 from blood erythrocytes, and 
capturing the antibody-TG2 complex to immobilized FN (Korponay-Szabó et 
al. 2005). 
The time-dynamics of the anti-TG2 IgA antibodies in the sera of CD 
patients, like EmA-IgA, follows gluten consumption (Bürgin-Wolff et al. 2002). 
The sensitivity of anti-TG2 IgA is considered lower in children under two years 
of age, and the assessment of AGA or AdGA is suggested as a complimentary 
test (Bürgin-Wolff et al. 2002; Agardh 2007; Lagerqvist et al. 2008). Epidemio-
logical studies have described the first appearance of AGA, followed by anti-
TG2 antibodies in children at genetic risk of CD (Liu et al. 2007; Simell et al. 
2007). The phenomenon of the spontaneous disappearance of the anti-TG2 
antibodies in about half of the gluten-consuming children, who had positive 
results earlier, has also been reported (Simell et al. 2007).  
The production of anti-TG2 antibodies in the intestinal mucosa of CD 
children is demonstrated by antibody deposits colocalizing with TG2 
(Korponay-Szabó et al. 2004), as well as by characterisation of the anti-TG2 
antibody clones from the gut (Marzari et al. 2001). Detection of anti-TG2 IgA 
deposits in the intestinal mucosa of CD patients is suggested as an additional 
diagnostic tool in seronegative CD patients (Salmi et al. 2006a), and also as a 
predictive marker for forthcoming CD (Salmi et al. 2006b). 
 
 
2.4.4. Anti-cytoskeletal antibodies 
The presence of smooth muscle antibodies (SMA) of the IgA class have been 
observed in CD patients when studying serum antibody binding in IIF studies, 
although in lower titers and with less sensitivity and specificity than EmA-IgA 
(Uibo et al. 1995; Volta et al. 1995; Amara and Husebekk 1998). However, in 
some cases masking of the EmA-IgA pattern by SMA-IgA staining can occur, 
and by increasing the serum dilution, EmA-IgA detection can be improved 
(Lasagni et al. 1999). 
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SMA types are classified according to the staining pattern on different 
tissues (Bottazzo et al. 1976), and are mainly related to antibodies against 
different cytoskeletal proteins which are making up microfilaments, 
intermediate filaments and microtubules (Dighiero et al. 1990; Toh 1991). Both 
IgG class SMA and antibodies to individual cytoskeletal proteins, especially to 
actin, are associated with autoimmune hepatitis (Whittingham et al. 1966; 
Mackay et al. 2008), but low titer and transient SMA/anti-cytoskeletal anti-
bodies have been found in various disease conditions (Bottazzo et al. 1976; Toh 
1991), and also in the general population (Uibo et al. 1998). Autoantibodies 
reacting with microfilaments primarily recognize actin (Bottazzo et al. 1976; 
Mackay et al. 2008), whereas antibodies reacting with intermediate filaments 
are specific to vimentin and desmin proteins (Kurki and Virtanen 1985; 
Dighiero et al. 1990). Autoantibody binding depends on the conformation of the 
cytoskeletal proteins, as, for example, polymerised, filamentous actin is 
recognized more frequently than monomeric actin by autoantibodies of auto-
immune hepatitis patients (Mackay et al. 2008). Therefore, considerable 
differences exist between anti-cytoskeletal antibody binding to tissues or cells 
by IIF histochemistry and to individual cytoskeletal proteins using the ELISA 
and western blot methods (Girard and Senécal 1995; Mackay et al. 2008). 
Clemente and colleagues described the presence of gluten-dependent, mainly 
IgA class serum autoantibodies against filamentous actin in 71% of CD patients 
using IIF on HEp-2 cells (Clemente et al. 2000). The diagnostic value of anti-
actin antibodies for CD, detected by IIF, ELISA, or both, was assessed in 
follow-up studies, and the association with the degree of mucosal lesion was 
revealed (Clemente et al. 2004; Granito et al. 2004; Carroccio et al. 2007). 
However, the lower diagnostic performance of anti-actin IgA compared to anti-
TG2 IgA has given no support for the use of anti-actin antibodies in CD 
screening, but rather as an additional test for specific disease cases (Fabbro et 
al. 2008; Bazzigaluppi et al. 2010). 
 
 
2.4.5. Other CD-associated autoantibodies 
Autoantibodies against other self-proteins can be associated with CD or with 
extraintestinal manifestations of the disease. Transglutaminase 3 (TG3) or 
epidermal transglutaminase has been identified as the target antigen in DH, a 
skin disease closely associated with CD (Sárdy et al. 2002). In addition to the 
small intestinal lesions characteristic of CD, and circulating anti-TG2 IgA, 
patients with DH have anti-TG3 IgA antibodies in their blood and antigen-
antibody deposits in the skin (Sárdy et al. 2002; Cannistraci et al. 2007; Hull et 
al. 2008). TG3 is expressed in keratinocytes, and is involved in cell envelope 
formation during keratinocyte differentiation (Griffin et al. 2002). Supported by 
experimental data, diffusion of TG3 from the epidermis and anti-TG3 IgA from 
the blood circulation leads to the formation of immune complexes in the 
papillary dermis in DH patients (Zone et al. 2011). Epitope spreading from TG2 
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to TG3 has been proposed as a mechanism for the development of anti-TG3 IgA 
antibodies in DH patients (Sárdy et al. 2002; Zone et al. 2011). A distinct 
population of antibodies against TG6, a recently described neuronal trans-
glutaminase, is suggested to be associated with cerebellar ataxia in a subgroup 
of patients with the gluten-sensitive type of this neurological disease (Hadji-
vassiliou et al. 2008). In addition to antibodies against TG3 and TG6, cross-
reactive anti-TG2 antibodies could recognize other members of the TG family, 
although this has not been experimentally studied (Alaedini and Green 2008). 
Calreticulin, a multifunctional intracellular protein, was identified as an 
enterocyte antigen cross-reactive with the anti-gliadin antibodies of CD patients 
(Tučková et al. 1997). IgA and IgG class antibodies against calreticulin were 
found at significantly higher levels in the sera of CD patients compared with 
healthy controls, and the levels decreased in response to a GFD (Sánchez et al. 
2000). However, antibodies to calreticulin also occur in various autoimmune 
and infectious diseases (Sánchez et al. 2003). Also neuronal protein synapsin I 
was shown to be recognised by anti-gliadin antibodies, and such antibodies 
were detected in several patients with CD (Alaedini et al. 2007). IgA antibodies 
against the tight junction regulatory protein zonulin, the expression of which is 
increased in the small intestinal mucosa of CD patients, have been detected in 
about a fifth of CD patients with the acute phase of the disease (Fasano et al. 
2000). In smaller subsets of CD patients, autoantibodies were identified 
targeting osteoprotegerin in association with osteoporosis (Riches et al. 2009), 
or ATP synthase β chain and enolase α, the clinical relevance of which 
remained elusive (Stulík et al. 2003).  
Several autoantibodies occurring in CD can be affiliated with an associated 
disease rather than with enteropathy itself. Antibodies against gangliosides, a 
type of glycolipid expressed on neuronal cells, were described in CD patients 
with neurological disorders (Alaedini et al. 2002; Volta et al. 2006). Similarly, 
autoantibodies associated with type 1 diabetes, autoimmune thyroiditis and 
some other autoimmune conditions can be observed as more prevalent in CD 
patients than in the general population (Shaoul and Lerner 2007). 
 
 
2.4.6. Autoantibodies in the pathogenesis of CD 
The question of whether and how autoantibodies contribute to CD pathogenesis 
has been addressed in many studies, the majority exploring the effect of anti-
TG2 antibodies on the enzymatic activity of TG2 and on various cellular 
functions in vitro (Caputo et al. 2009; Caja et al. 2011). The epitope analysis of 
TG2, providing possible insights into the functional role of autoantibodies, has 
revealed that intact N-terminal, catalytic, and C-terminal domains are needed 
for antibody binding (Seissler et al. 2001; Sblattero et al. 2002; Nakachi et al. 
2004; Byrne et al. 2007; Simon-Vecsei et al. 2012). A recent study identified a 
conformational epitope of TG2, involving amino acid residues Glu-153 and 
Glu-154 in the catalytic domain, and Arg-19 in the N-terminal domain, as the 
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main autoantibody binding site for anti-TG2 autoantibodies in CD patients 
(Simon-Vecsei et al. 2012). 
A review of the studies shows that the effects of anti-TG2 antibodies of CD 
patients on the main biochemical activity of TG2 – transamidation, vary from 
the inhibition (Esposito et al. 2002; Dieterich et al. 2003; Byrne et al. 2010) to 
the enhancement of enzyme activity (Király et al. 2006; Myrsky et al. 2009). 
Although methodological differences may account for some of the variability in 
the results, autoantibody populations with opposite effects on TG2 transami-
dation activity may exist in the sera of patients with CD (Király et al. 2006). 
According to the recent report, the effect of autoantibodies on TG2 transami-
dation activity can be indirect, as the binding of anti-TG2 antibodies to the cell-
surface activated the intracellular TG2 pool through the modulation of Ca2+ 
homeostasis (Caputo et al. 2012). 
TG2 is involved in multiple cellular processes and the effects described for 
anti-TG2 antibodies from CD patients in various cell culture models are wide 
ranging: inhibiting differentiation (Halttunen and Mäki 1999) and increasing 
proliferation of intestinal epithelial cells (Barone et al. 2007a), disturbing 
angiogenesis (Halttunen and Mäki 1999; Myrsky et al. 2008; Caja et al. 2010), 
increasing intestinal (Zanoni et al. 2006) and endothelial cell permeability 
(Myrsky et al. 2009), modulating endocytosis of gliadin peptides (Caputo et al. 
2010), and inducing apoptosis in trophoblastic cells (Di Simone et al. 2010). 
These findings are explained either by the modulation of the transamidation 
activity of TG2 by autoantibodies (Myrsky et al. 2009; Caja et al. 2010), 
disorganising the actin cytoskeleton of the cells (Barone et al. 2007a; Myrsky et 
al. 2008), or by interfering with the outside-in signalling of cell surface TG2-
integrin complexes (Barone et al. 2007a; Caputo et al. 2010). The increase of 
ERK phosphorylation (Caputo et al. 2010), and activation of small GTPase 
RhoA (Myrsky et al. 2009) in cells have been observed in response to treatment 
with anti-TG2 autoantibodies. TG2 is required for the formation of active TGF-
β from the latent TGF-β complex (Nunes et al. 1997), therefore the role of anti-
TG2 autoantibodies hindering this process, and consequently cellular differen-
tiation, has been proposed (Halttunen and Mäki 1999). 
The possible pathogenic effects of anti-TG2 antibodies have been also 
studied in animal models, closely resembling situation at organism level. A 
systemic immune response was induced in mice when immunized with hrTG2, 
including the appearance of anti-TG2 IgG antibodies in the sera, and the 
development of focal lymphocytic infiltrates in the lacrimal glands, but not in 
the intestine or in the skin (Freitag et al. 2004). When expressing anti-TG2 
single chain antibody fragments cloned from CD patients in a mouse model no 
apparent pathologies or antibody deposits were observed at the tissue level but 
mice developed strong anti-idiotypic antibody responses (Di Niro et al. 2008). 
Transient cerebellar ataxia, thought to occur through antibody-antigen 
interaction at the vascular level was induced in the animals by injecting 
monoclonal human anti-TG2 antibodies into the central nervous systems of the 
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mice (Boscolo et al. 2010). It has also been demonstrated that sera from DH 
patients transferred to human skin-grafted mice mimics DH immunopathology 
(Zone et al. 2011). These results would not support a central role for anti-TG2 
antibodies in CD pathogenesis. However, no definitive conclusions can be made 
for human CD, based on animal studies only, while not modelling CD with 
chronic inflammation and increased vascular permeability (Di Niro et al. 2008). 
The presence of anti-TG2 antibody deposits in the small intestinal lesions of CD 
patients in the early phase of the disease (Korponay-Szabó et al. 2004), as well 
as in extraintestinal tissue (Sárdy et al. 2002; Hadjivassiliou et al. 2008), and 
the biological effects of anti-TG2 antibodies obtained in vitro and in vivo, 
would suggest an active role for anti-TG2 antibodies in inflammation and tissue 
remodelling in CD. 
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3. AIMS OF THE STUDY 
1. To detect the presence of anti-cytoskeletal antibodies in the sera of CD 
patients and to identify the main cytoskeletal antigen(s); to compare the 
diagnostic value of anti-cytoskeletal antibodies and anti-TG2 antibodies, and 
to evaluate the impact of a gluten free diet on autoantibody levels (Study I). 
2. To compare the diagnostic performance of an anti-TG2 ELISA, based on 
TG2 binding to fibronectin, with a conventional ELISA for serum anti-TG2 
IgA, IgG and IgM assessment in children with CD (Study II). 
3. To evaluate the effect of anti-TG2 antibodies from the sera of CD patients 
on TG2 interactions with heparin/heparan sulphate and on the TG2-
dependent adhesion of intestinal epithelial cells (Study III). 
4. To delineate the main heparin-binding regions of TG2 by biosensor analysis 
of the putative heparin-binding TG2 peptides; to characterize immuno-
reactivity and the effect on cell adhesion of the heparin-binding TG2 
peptides (Study IV). 
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4. MATERIAL AND METHODS 
4.1. Study subjects 
Blood sera from 436 children and adolescents were studied, including 216 
patients with CD and 220 diseased or healthy control subjects. The general 
characteristics of the study groups are provided in Table 1. Patients were 
enrolled at two centres: the Children’s Clinic, Tartu University Hospital in 
Estonia, from 1990–2009 (n = 221), and the Department of Pediatrics, Malmö 
University Hospital at Lund University in Sweden, from 2000–2007 (n = 215). 
The informed consent of the participants and/or their parents was obtained for 
the intended use of the serum samples. The studies were approved by the Ethics 
Review Committees on Human Research of the University of Tartu and Lund 
University. Serum samples were stored at –20°C or at –75°C for longer storage.  
 
Celiac disease group 
Celiac disease was diagnosed in 216 children (73 from Estonia, 143 from 
Sweden) in accordance with the European Society of Pediatric Gastro-
enterology, Hepatology and Nutrition (ESPGHAN) criteria (Walker-Smith et al. 
1990), based on biopsy findings of the small intestinal mucosa, characteristic of 
CD. According to the degree of mucosal lesion, intraepithelial lymphocytosis 
(Marsh grade I–II) was observed in 7 patients; partial villous atrophy (Marsh 
IIIa) was detected in 46 patients, subtotal villous atrophy (Marsh IIIb) in 95, and 
total villous atrophy (Marsh IIIc) in 56 patients; 9 patients had undifferentiated 
Marsh III grade lesions. Three patients refused intestinal biopsies, but were 
included in the study group because of their clinical symptoms of CD and high 
anti-TG2/EmA levels. The following associated disease conditions were 
diagnosed in CD patients: type 1 diabetes (n = 20), IgA-deficiency (n = 3), iron 
deficiency anaemia (n = 2), DH (n = 1), gastritis (n = 1), epilepsy (n = 1), 
Turner’s syndrome (n = 1), Down’s syndrome (n = 1). Sera were obtained at the 
same time as the small intestinal biopsy or up to 1 month before. Serum samples 
from 26 patients on a GFD for 6–18 months (mean 9.6 months) were also 
studied (Study I). 
 
Control groups 
The biopsy control group included 122 patients (50 from Estonia, 72 from 
Sweden), who had undergone upper endoscopies to exclude CD, and had 
normal intestinal mucosa on histological examination. Most of the patients  
(n = 82) had no established diagnosis with recurrent abdominal pains, 
temporary gastrointestinal symptoms, or growth problems as the main 
symptoms. Other disease conditions in this group were food allergies (n = 12), 
gastritis (n = 9), selective IgA-deficiency (n = 8), lipase deficiency (n = 3), 
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esophagitis (n = 3), duodenal ulcers (n = 2), iron deficiency anaemia (n = 1), 
Down’s syndrome (n = 1) and chromosome 18p deletion syndrome (n = 1). The 
disease control group consisted of 50 children, diagnosed at the Children’s 
Clinic, Tartu University Hospital with the following disease conditions: type 1 
diabetes (n = 26), juvenile chronic arthritis (n = 14), reactive arthritis (n = 6), 
systemic connective tissue disorders (n = 3), and muscular dystrophy (n = 1). 
The healthy children (n = 48) were recruited during regular medical 
examinations at the Children’s Clinic, Tartu University Hospital. No intestinal 
biopsies were performed among healthy children and disease controls. 
 
Table 1. General characteristics of the study groups and involvement of subjects in 
studies (I–IV). 






Total, n 216 122 50 48 
Origin, Estonia/Sweden 73/143 50/72 50/0 48/0 
Female, n (%) 136 (63.0) 58 (47.5) 25 (50.0) 24 (50.0) 
Median age, years  5.2 7.0 8.0 4.0 
Age range, years 0.6–21.1 0.6–22.2 2.0–15.0 0.5–14 
Study I, n 42 18 50 48 
Study II, n 173* 97* – – 
Study III, n 27 13 – – 
Study IV, n 10 11 – – 
* Including 143 patients with CD and 72 biopsy controls from Department of Pediatrics, Malmö 
University Hospital at Lund University, Sweden  
 
 
Use of patient samples in different studies 
In Study I, where the main focus was on defining the autoantigenic targets of 
CD and on the diagnostic significance of the corresponding autoantibodies, 
patients with CD (n = 42) and control subjects (biopsy controls, n = 18; disease 
controls, n = 50; healthy controls, n = 48) were recruited at the Children’s 
Clinic, Tartu University Hospital in Estonia. Sera from Swedish patients (CD,  
n = 143; biopsy controls, n = 72) were used together with samples of Estonian 
origin (CD, n = 30; biopsy controls, n = 25) in Study II, in which the main 
objective was the comparison of two methods for anti-TG2 determination. 
Serum samples from CD patients and biopsy controls were also collected in 
Tartu for Study III (CD, n = 27; biopsy controls, n = 13) and Study IV (CD,  
n = 10; biopsy controls, n = 11), which focussed on the effect of anti-TG2 
antibodies on TG2 binding to heparin/HS and the related cell adhesion function. 
Only sera from CD patients positive for anti-TG2 IgA or IgG were selected for 
these two studies.  
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4.2. Antibodies and peptides 
Mouse monoclonal anti-TG2 antibodies (clone CUB7402), anti-tubulin anti-
bodies (clones DM1A+DM1B), and rabbit polyclonal anti-TG2 antibodies were 
obtained from Thermo Fisher Scientific (Fremont, USA), mouse monoclonal 
anti-vimentin antibodies (clone V9) and rabbit anti-desmin antisera were from 
Sigma-Aldrich (St. Louis, USA), mouse monoclonal anti-actin (clone C4) was 
from Boehringer Mannheim (Mannheim, Germany), and rabbit polyclonal anti-
human FN antibodies were from DakoCytomation (Glostrup, Denmark). 
The amino acid sequences of peptides used in the studies are shown in 
Table 2. Integrin-binding RGD peptide (G1269) and a control peptide with no 
effect on integrin function (S3771) were from Sigma-Aldrich (St. Louis, USA). 
TG2 peptides and a control peptide from enterovirus VP1 protein, which is a 
common epitope for all known enteroviruses (Viskari et al. 2004), were 
synthesized by Storkbio Ltd (Tallinn, Estonia) using Fmoc chemistry and 
purified by reversed-phase HPLC to over 95% purity. Peptides were analyzed 
with MALDI-TOF mass spectrometry for correct molecular weight. TG2 
peptides were selected based on the predicted heparin/HS binding sequences in 
the protein, as described earlier (Utt et al. 2001); peptide P3 represented the 
TG2 control peptide (Zanoni et al. 2006). 
 
Table 2. Synthetic peptides used in the studies. The parent molecule, peptide location in 
protein sequence, as well as the theoretical pI and molecular weight of the peptides are 
shown. Lysin (K) and arginine (R) residues are underlined. 
Peptide Parent molecule Position Sequence Theoretical pI/Mw 
P1 Human TG2 202215 KFLKNAGRDCSRRS 10.9/1637.9 
P2 Human TG2 261274 LRRWKNHGCQRVKY 11.0/1844.2 
P31 Human TG2 476487 RIRVGQSMNMGS 12.0/1335.6 
P4 Human TG2 590603 KIRILGEPKQKRKL 11.2/1707.1 
P5 Human TG2 671681 DKLKAVKGFRN 10.3/1275.5 
VP12 Enterovirus VP1 ND KEVPALTAVETGATC 4.5/1489.7 
RGD ND ND GRGDSPK 8.8/715.7 
DGR ND ND SDGRG 5.6/490.4 
1 Zanoni et al. 2006; 2Viskari et al. 2004; ND – not defined 
 
 
4.3. Preparation of antigens 
Cytoskeletal proteins 
In Study I, the human umbilical cord (HUC) was used as the antigenic source 
for extraction of cytoskeletal proteins for autoantibody screening. While the 
HUC was the antigenic substrate for detection of both EmA-IgA and SMA-IgA 
37 
by IIF, the same tissue was chosen for searching candidate cytoskeletal 
antigens. A complex extraction protocol was developed to achieve the 
enrichment of a 57 kDa candidate antigen, identified as the intermediate fila-
ment protein desmin. Using western blot analysis, the other major components 
of the desmin-enriched extract were identified as vimentin and actin. In order to 
get more purified desmin for an ELISA analysis, desmin was prepared from the 
smooth muscle of chicken (the gizzard) according to a published protocol 
(Geisler and Weber 1980). Buffers containing 6 M urea were used in both 
methods to solubilise cytoskeletal proteins.   
 
TG2 
Human recombinant TG2 was produced in order to develop an ELISA assay 
(Study II) to investigate the biological effects of anti-TG2 antibodies (Study 
III), and to study the binding characteristics of TG2 to heparin (Study IV). Our 
approach was designed to obtain sufficient recombinant TG2 while retaining the 
biological activity of the protein. Using human TG2 cDNA (Genbank accession 
no 55153) (Gentile et al. 1991) as the template, a plasmid vector was designed 
encoding human full length TG2 with a C-terminal polyhistidine tag (amino acids 
RSHHHHHH), and transformed into E. coli. TG2 expression was induced by a 
low concentration (10 M) of isopropyl-β-D-thiogalactoside (IPTG) at 25°C to 
increase the yield of soluble TG2. A two-step purification of hrTG2 was per-
formed with subsequent Ni2+-chelate and anion-exchange chromatography to 
obtain recombinant protein purity of over 90%. The average amount of purified 
TG2 was 5 mg per litre of bacterial culture. The human recombinant TG2 posses-
sed transamidase activity, comparable to that of commercial gpTG2 (Slaughter et 
al. 1992), as well as the ability to bind to its natural ligand FN (Study II). 
 
 
4.4. SDS-PAGE, western blot, protein identification 
SDS-PAGE was performed on discontinuous 10% polyacrylamide gels, and 
separated proteins were stained with Coomassie Brilliant Blue G-250 or trans-
ferred to nitrocellulose membranes for probing with human sera or mono-
specific antibodies. Western blot was used for detecting IgA reactivity against 
human desmin (Study I), monitoring the expression, correct molecular weight 
and purity of hrTG2 (Study II), and analysing the protein composition of 
affinity purified anti-TG2 antibody samples (Study III). 
In Study I, the 57 kDa antigen of interest was identified as desmin, using 
peptide mass-mapping by MALDI-TOF mass spectrometry and direct sequence 
analysis of selected peptides by Edman degradation. The peptide masses were 
analysed using the ProFound program (http://prowl.rockefeller.edu/prowl-
cgi/profound.exe). The ten highest scores identified desmin from different 
species and all four sequences obtained corresponded to muscle desmin. 
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4.5. Detection of autoantibodies 
EmA and umbilical cord smooth muscle antibodies (uSMA) 
An IIF assay on cryosections of HUC was used to detect IgA class EmA and 
SMA in the sera of CD patients and the controls (Study I). Serum was con-
sidered positive for EmA-IgA when a typical staining pattern around the smooth 
muscle cells of the blood vessels was observed at 1:10 serum dilution (Ladinser 
et al. 1994). The intracellular staining of the smooth muscle cells was 




Since TG2 was identified as an autoantigen of EmA-IgA, an ELISA for anti-
TG2 IgA detection from the sera of CD patients was established using 
commercially available TG2 from guinea pig livers (Sigma-Aldrich) as the 
antigen (Dieterich et al. 1998; Sulkanen et al. 1998b). We used a similar ELISA 
in Study I to compare the diagnostic value of anti-desmin and anti-TG2 IgA 
antibodies for CD. Universal binding 96-well microtiter plates (Thermo Fisher 
Scientific Oy, Vantaa, Finland) were used. A consensus finding of advanced 
studies was the lower diagnostic accuracy of a gpTG2 based ELISA compared 
to those using human TG2 (Sblattero et al. 2000; Sárdy et al. 2002), so we 
developed ELISAs utilizing hrTG2 as the antigen in Study II. A novel ELISA 
using FN as the binding ligand for TG2 was compared with the traditional 
method for the detection of anti-TG2 antibodies of the IgA, IgG, and IgM 
classes in CD and the control groups. In the modified ELISA, instead of coating 
the plastic surface directly with hrTG, plate wells were coated first with purified 
human FN (F2006; Sigma-Aldrich) and then with hrTG2. Both assays were run 
in parallel with the same serum dilutions (1:100), and tested in duplicate wells 
on one plate. No human serum antibody reactivity with the wells only coated 
with FN was observed, whereas some conjugated secondary antibodies against 
human IgG and IgM had slightly higher background binding to FN, which was 
minimized by the selection of appropriate conjugate and dilution. Anti-TG2 
ELISA results were expressed in arbitrary units (AU) as percentages of the 
reference serum optical density values. The cut-off values were chosen to 
achieve high diagnostic specificity without significant loss of sensitivity. The 
intra- and inter-assay variability of the assays remained below coefficient of 
variation (CV)% value of 15. 
 
Anti-desmin ELISA 
An ELISA procedure similar to that of anti-gpTG IgA determination was used 
for anti-desmin IgA detection (serum dilution 1:100). The antibody levels were 
expressed in AU, and the same reference serum was used in the ELISA and 
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western blot for detection of anti-desmin IgA. The positive cut-off value was 




The reactivity of the heparin-binding synthetic peptides of TG2 with serum IgA 
from CD patients was estimated using a peptide ELISA in Study IV. Enhanced 
binding 96-well microtiter plates (Thermo Fisher Scientific Oy, Vantaa, 
Finland) were coated with peptides and air-dried. Patient and control sera were 




4.6. Affinity purification of autoantibodies 
The affinity purification of serum antibodies was carried out to characterize the 
antigen-specificity of anti-desmin antibodies (Study I) and the functional role of 
anti-TG2 antibodies (Study III). In Study I, chicken desmin (6 mg) was 
conjugated to divinylsulphone activated Sepharose CL-6B matrix (2 ml). Three 
serum pools (including one control, 0.5 ml each) were applied on separate 0.5 
ml columns and bound antibodies were eluted with 1 M potassium thiocyanate. 
Antibody samples were dialyzed against phosphate buffered saline (PBS) and 
tested for the presence of autoantibodies (anti-desmin, anti-TG2, EmA, uSMA). 
In Study III, hrTG2 protein (2 mg) was coupled to 2 ml of N-hydroxysuccini-
mide activated Sepharose 4 Fast Flow beads according to the manufacturer’s 
instructions (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). The affinity 
purification was performed with 13 sera from CD patients and 6 control sera 
(0.5 ml each) on two hrTG2-Sepharose columns (1 ml). Antibodies were eluted 
with acidic glycine buffer (pH 2.5) and columns were regenerated with 6 M 
guanidinium hydrochloride after each purification cycle. Antibody samples 
were dialyzed against PBS, concentrated by centrifugal ultrafiltration, and the 
protein concentration was determined by the Bradford method. Anti-TG2 IgA 
and IgG levels in samples were assessed by a quantitative ELISA. The average 
recovery of specific anti-TG2 IgA from sera was 35 ± 17% and no anti-TG2 









4.7. Biochemical analysis of TG2 
Transamidation assay 
A transamidation assay of FN bound TG2 was used (Uibo et al. 2011), based on 
the method by Király et al. (2006) to estimate the effect of anti-TG2 antibodies 
from CD patients on the enzymatic activity of TG2 in Study III. Human 
recombinant TG2 was immobilized to a FN coated surface and treated with 
human affinity purified anti-TG2 antibodies (10 g/ml) or CUB 7402 mono-
clonal anti-TG2 antibodies (5g/ml) with known transamidation-inhibiting 
properties. Thereafter, the incorporation of a 5-(biotinamido)-pentylamine 
substrate molecule was measured using alkaline phosphatase (AP)-conjugated 
streptavidin for detection (Pierce Biotechnology, Rockford, USA), and the 
results were expressed as percentages of OD values as compared to the control 
sample without antibodies. 
 
Heparin/HS binding assay 
In order to evaluate TG2 binding to heparin/HS and the effect of anti-TG2 anti-
bodies on this interaction, a method of protein binding to non-covalently 
immobilized heparin (Mahoney et al. 2004) was used in Study III. Heparin, 
heparan sulphate, or hyaluronic acid (Sigma-Aldrich) were used to coat Heparin 
Binding Plates (BD Biosciences, Bedford, USA) followed by incubation with 
TG2 at 2.5 g/ml. For the binding inhibition studies, TG2 was preincubated 
either with heparin (0.25–64 g/ml), human sera (dilution 1:100) or affinity 
purified anti-TG2 antibodies (20 g/ml) before applying it to the wells. The 
binding of TG2 was detected with mouse monoclonal anti-TG2 antibodies 
(CUB7402) and subsequently with AP-conjugated rabbit anti-mouse Ig 
antibodies (Dako, Glostrup, Denmark). The substrate colour absorbance was 
read at 405/492 nm and the binding of TG2 in inhibition experiments was 
expressed as percentages of the results obtained without antibodies. 
 
Surface plasmon resonance 
In order to characterize the affinity of TG2 and its putative heparin-binding 
peptides to heparin, surface plasmon resonance (SPR) analysis was performed 
with a Biacore 3000 instrument (Biacore AB, Uppsala, Sweden), enabling real-
time monitoring of binding kinetics. Heparin was biotinylated via a reducing 
terminus (Osmond et al. 2002), and immobilized onto a streptavidin coated 
CM5 sensor chip. Binding of hrTG2 (5–100 nM) and synthetic peptides  
(5–67.5 M) were measured at flow rates 10 l/min and 20 l/min. In binding 
competition experiments, TG2 was incubated with soluble heparin or 
hyaluronic acid for 15 min before injecting the mixture into heparinized surface. 
Surface regeneration to baseline was achieved with 1 M NaCl. A control 
sensorgram, obtained from a flow cell coated only with streptavidin, was always 
subtracted from the binding sensorgram, and the data was analyzed using 
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BIAevaluation software 3.1 (Biacore AB). The binding rate constants (ka, kd) 
and the dissociation equilibrium constant (Kd) were calculated using a Langmuir 
1:1 binding model and a global fitting algorithm for concentration series.  
 
 
4.8. Cell attachment studies  
Cell lines 
In Studies III and IV, the Caco-2 human colon adenocarcinoma cell line 
(American Type Culture Collection, Rockville, USA) was used in cell 
attachment experiments. Cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% foetal bovine serum and indicated supplements 
(PAA Laboratories GmbH, Pasching, Austria). Cells were maintained at 37°C 
in a 5% CO2 environment and passaged or used in the experiment when 
reaching 80–90% confluence. 
 
Cell attachment assay 
Cell attachment was evaluated according to the method described by Balklava 
et al. (2002). Ninety six-well cell culture plates (BD Biosciences, Bedford, 
USA) coated with human FN or FN and TG2 (FN-TG2), were treated with 
dilutions of human sera (1:50) or affinity purified antibodies (20 g/ml) for one 
hour or left untreated. Then trypsin-ethylenediaminetetraacetic acid (EDTA) 
detached Caco-2 cells were incubated for 15 min at room temperature with the 
adhesion inhibiting (RGD), adhesion control (DGR), or TG2 peptides P1–P3 
(20 g/ml, 100 g/ml), and seeded on FN or FN-TG2 coated wells. Cells were 
allowed to attach for 90 min at 37°C, and after a gentle wash, were fixed and 
stained with crystal violet. After this, the stain was solubilised and the 
absorbance was read at 540 nm by a spectrophotometer. The results were 
expressed as the percentage normalized to the cell attachment in the presence of 
the DGR control peptide at 20 g/ml (100%). 
 
Fluorescence staining of cells 
Fluorescence staining of cells was performed in Study III to visualize the Caco-
2 cell attachment on the FN and FN-TG2 surface in various conditions. FN and 
FN-TG2 coated 8-well chamber glass slides (Nalge Nunc International, 
Rochester, USA) were treated with human serum dilutions, and the Caco-2 cells 
were allowed to attach for 2 hours, as described in the previous paragraph. 
Attached cells were fixed with 3.7% paraformaldehyde, permealized with 0.2% 
Triton X-100, and then the actin filaments were made visible with Alexa Fluor 
594 phalloidin (Invitrogen Molecular Probes, Eugene, USA). Slides were 
examined under an Olympus IX70 fluorescence microscope (Olympus Corpora-




Statistical analyses were performed using MedCalc software (Mariakerke, 
Belgium). The following parametric and nonparametric statistical tests were 
used for data analysis: one way analysis of variance (ANOVA) for comparison 
of the groups with an additional Student-Newman-Keuls test for pairwise 
comparisons (Study III); repeated measures ANOVA for comparing peptides’ 
immunoreactivity; Student’s t-test for independent samples for comparing other 
datasets (Study IV); the Mann-Whitney U-test for comparison of the antibody 
values between the groups (Study I); Fisher’s exact test (Study I) and 
McNemar’s paired proportion test (Study II) for comparing antibody 
prevalences; Pearson’s test (Studies III, IV) and Spearman’s rank test (Studies I, 
II) for correlation analysis; regression analysis and the Kruskal-Wallis test for 
associations of assay values with age and degree of mucosal lesion, respectively 
(Study II). The areas under the receiver operating characteristic (ROC) curves 
of two assays in Study II were compared according to the method of Hanley and 
McNeil (1983). p < 0.05 was considered significant in all analyses. Average 




5.1. Anti-desmin IgA antibodies (Study I) 
Identification and prevalence of anti-desmin IgA in CD 
The starting point of this study was the observation of a SMA type IgA antibody 
staining pattern in some of the CD patients when tested for EmA-IgA on tissue 
sections (Uibo et al. 1995; Volta et al. 1995; Amara and Husebekk 1998). SMA-
IgA detection by IIF might be underestimated in CD because of strong EmA-
IgA staining, therefore, the western blot method was chosen to detect IgA 
antibodies against cytoskeletal antigens, the main protein targets of SMA. 
Serum IgA of many CD patients recognized a 57 kDa antigen in a crude 
cytoskeletal extract of HUC. Enrichment of the 57 kDa protein was obtained 
after further extraction steps with other dominant proteins at 45 kDa, 59 kDa, 
and over 200 kDa (Figure 3). The 57 kDa protein band was excised from the gel 
and, after protease (trypsin or endoproteinase LysC) treatment, subjected to 
identification by peptide mass-mapping using MALDI-TOF mass spectrometry 
and by amino acid sequencing of selected peptides. Both methods clearly 
identified the 57 kDa antigen as the muscle specific intermediate filament 
protein, desmin. The result was also confirmed by rabbit anti-desmin polyclonal 
antibodies reacting with the 57 kDa antigen on western blots. The proteins of 45 
kDa and 59 kDa were stained by mouse monoclonal anti-actin and anti-
vimentin antibodies, respectively. Mouse monoclonal anti-TG2 antibodies also 
recognized a narrow band at 85 kDa (Figure 3). 
 
Figure 3. SDS-PAGE of cytoskeletal extracts from HUC and western blot with control 
antibodies and human serum IgA. Crude cytoskeletal extract (lane I) and desmin-
enriched extract (lane II), separated on 10% polyacrylamide gel and stained with 
Coomassie Brilliant Blue G-250. Western blot of desmin-enriched extract with: mouse 
monoclonal antibodies to tubulin (lane 1), to TG2 (lane 2), to actin (lane 3), to vimentin 
(lane 4), rabbit polyclonal antibodies to desmin (lane 5), anti-desmin positive control 
serum (lane 6), negative control serum (7), and sera from patients with CD (8–12). 
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Table 3. Prevalence of IgA autoantibodies in sera of CD patients and controls. 





















































1 Including 18 biopsy controls and 50 patients with other diseases 
* p < 0.05 compared with untreated CD (Fisher’s exact test) 
CD, celiac disease; WB, western blot; 
 
 
Positive IgA reactions against human desmin on blots were detected in 22 of the 
42 (52.4%) patients with CD and in 12 of the 116 (10.3%) control subjects 
(Figure 3; Table 3). The protein bands corresponding to actin and vimentin were 
only recognized by the IgA of four CD patients in each case. Two sera from CD 
patients reacted with all three cytoskeletal proteins but no sera recognized the 
85 kDa band corresponding to TG2. 
When the same sera were tested for anti-desmin IgA by an ELISA, 
using purified chicken desmin as the antigen, the antibody results correlated 
significantly with those obtained in the WB assay in patients with untreated CD 
(r = 0.65, p < 0.001). A similar proportion of CD sera was positive in anti-des-
min ELISA (50.0%), although many sera were positive in one assay only. The 
discrepancy in the results were mainly due to the different immunoreactivity of 
human and chicken desmin (sharing 84% amino acid sequence identity), but 
were also due to the differences in the methods used. The uSMA-IgA was 
detected less frequently in the CD sera (16.7%) than anti-desmin IgA 
antibodies, but the frequency in the control sera (11.2%) was similar to that of 
anti-desmin IgA (10.3%). However, the majority of the uSMA-IgA positive sera 
(63.6%) were positive for at least one of the anti-desmin IgA tests.  
 
Comparison of anti-desmin and anti-TG2 IgA  
In order to estimate the diagnostic value of anti-desmin IgA for CD, anti-desmin 
antibody results were compared with most accurate antibody markers for CD, 
EmA-IgA and anti-TG2 IgA. Both assays were positive in 71.4% of patients 
with untreated CD, representing diagnostic sensitivity. Although higher than the 
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sensitivity of anti-desmin IgA, this number was considerably lower than the 
sensitivity of EmA-IgA and anti-TG2 IgA for CD reported previously 
(Dieterich et al. 1998; Sulkanen et al. 1998b). We explained the low anti-TG2 
seropositivity with the high proportion of very young patients in our CD group 
(60% of CD patients were under 2 years of age). Eight of the 10 EmA-IgA and 
anti-TG2 negative CD patients where under the age of 2, and 6 of those were 
positive for AGA, as detected by ELISA (Uibo and Maaroos 1993). 
Anti-desmin IgA and anti-TG2 IgA levels, determined by ELISA, were 
significantly correlated among CD patients’ sera (r = 0.53, p < 0.001). Twenty 
six of the 30 CD patients with elevated anti-TG2 IgA had positive results in at 
least one anti-desmin IgA antibody test. Conversely, anti-TG2 IgA was detected 
in 19 of 21 sera positive in ELISA for anti-desmin IgA and in all 22 sera 
positive in WB. Moreover, the levels of anti-desmin IgA and anti-TG2 IgA 
changed in parallel in CD patients after a period of a GFD (Table 2 in Study I). 
In order to examine the possible serum IgA cross-reactivity between desmin 
and TG2, serum preadsorption experiments, as well as affinity purification of 
anti-desmin antibodies from CD patients’ sera, were performed. The results 
confirmed the specificity of anti-desmin IgA antibodies, as only soluble desmin, 
but not TG2, reduced or abolished IgA binding to the human desmin on the WB 
(Table 3 in Study I). More directly, affinity-purified anti-desmin IgA antibodies 
from CD patients’ sera recognized both human and chicken desmin on blots 
(Figure 4 in Study I), but had no reactivity against TG2 in the ELISA. 
Moreover, affinity purified anti-desmin IgA stained smooth muscle cells on 
HUC tissue in a similar pattern to uSMA-IgA, while the EmA-IgA reactivity 
detected in the original serum could not be found (Figure 4).  
 
 
Figure 4. Serum antibody staining on HUC tissue sections by IIF microscopy (original 
magnification 150). (A) EmA-IgA binding pattern (surrounding smooth muscle cells 
of umbilical blood vessel) by CD patient’s sera. (B) Staining of smooth muscle cells by 
affinity purified anti-desmin IgA antibodies from EmA-IgA positive CD patient’s sera. 




5.2. Comparison of anti-TG2 ELISAs (Study II) 
The new generation of antibody assays for anti-TG2 IgA detection, using 
human TG2 as the antigen, have reached a diagnostic accuracy for CD 
screening as high as 93% sensitivity and 98% specificity (Lewis and Scott 
2006). However, in a number of studies lower diagnostic specificities of anti-
TG2 IgA assays compared to the EmA-IgA test have been reported (Villalta et 
al. 2005; Bizzaro et al. 2006; Carroccio et al. 2007; Sárdy et al. 2007). Keeping 
this in mind, we modified an ELISA for anti-TG2 detection by binding hrTG2 
to its high affinity ligand FN. The purities of the protein components used in the 
assay are presented in Figure 5, showing that over 90% purity of hrTG2 was 
achieved after two-step chromatographic purification. 
The diagnostic performance of the FN-TG2 ELISA was compared with the 
traditional ELISA for the detection of anti-TG2 antibodies in the sera of CD 
patients and biopsy controls. ROC analysis was used to compare the tests 
estimating the diagnostic sensitivity and specificity at every possible cut-off 
level, which can be expressed as the area under the curve (AUC) value (Zweig 
and Campbell 1993). ROC curves for each Ig class assay are represented in 
Figure 6, showing that the detection of IgA class anti-TG2 antibodies was most 
effective for distinguishing between the CD and control subjects. The area 
under the ROC curve was high for both ELISAs detecting IgA antibodies  
(0.977 for FN-TG2-IgA and 0.970 for TG2-IgA). Compared to the IgA 
antibodies, AUC values were lower for assays detecting anti-TG2 IgG or IgM 
antibodies, but here the FN-TG2 ELISA (AUC = 0.930 for IgG, AUC = 0.850 
for IgM) performed significantly better than the corresponding TG2 ELISA 
(AUC = 0.809 for IgG, p < 0.001; AUC = 0.811 for IgM, p = 0.019). 
 
 
Figure 5. SDS-PAGE and western blot analysis of human purified recombinant TG2. 
Protein samples were separated on 10% polyacrylamide gels and stained either with 
Coomassie Brilliant Blue G-250 or western blotted with monoclonal anti-TG2 antibody: 
hrTG2 purified by Ni2+-chelate chromatography (lane 1), hrTG2 after additional ion-
exchange chromatography (lane 2), purified FN from human plasma (lane 3). 
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Figure 6. ROC curves for FN-TG2 and TG2 ELISAs for anti-TG2 IgA, IgG and IgM 
antibodies. Areas under the curve, representing overall diagnostic accuracy, were: (A) 
0.977 for FN-TG-IgA and 0.970 or TG2-IgA (p = 0.356); (B) 0.930 for FN-TG2-IgG 
and 0.809 for TG2-IgG (p < 0.001); (C) 0.850 for FN-TG2-IgM and 0.811 for TG2-IgM 
(p = 0.019). 
 
 
The anti-TG2 antibodies are the preferred serologic marker for screening CD 
and instrumental for intestinal biopsy (Lewis and Scott 2006), so a high 
diagnostic specificity (99–100%) was required for selecting the cut-off values in 
our study (Table 4). At these settings, the diagnostic sensitivity of all three  
FN-TG2 ELISAs (92.5% for IgA, 60.7% for IgG, 50.3% for IgM) was 
significantly higher than that of the corresponding TG2 ELISAs (89.0% for 
IgA, 48.6% for IgG, 38.7% for IgM). 
 
Table 4. Median antibody levels and diagnostic accuracy of FN-TG2 ELISAs and TG2 


















FN-TG2-IgA  8 72 (0–147) 160 92.5* 0 (0–7) 0 100.0 
TG2-IgA   12 73 (0–167) 154 89.0 2 (0–11) 0 100.0 
FN-TG2-IgG  12 17 (0–131) 105 60.7* 1 (0–19) 1 99.0 
TG2-IgG   16 15 (2–113) 84 48.6 6 (1–24) 1 99.0 
FN-TG2-IgM  8 8 (0–208) 87 50.3* 1 (0–7) 0 100.0 
TG2-IgM   18 13 (1–179) 67 38.7 5 (1–17) 0 100.0 
 AU, arbitrary units; CD, celiac disease. 




The better differentiation between the CD and control patients using the FN-
TG2 ELISAs was mainly due to the lower reactivity of the control sera in the 
FN-TG2 assay compared to the TG2 ELISAs, while in the CD patients the 
median antibody levels remained similar in both assays. This enabled lower cut-
off values in the FN-TG2 ELISAs, at the same assay specificity, to detect new 
positive CD cases with moderate anti-TG2 antibody levels and thus increase the 
diagnostic sensitivity of FN-TG2 assays for CD. 
The distribution of positive results among CD patients in all three FN-TG2 
assays (IgA, IgG, IgM) revealed that 117 (67.6%) of the patients were positive 
in at least two antibody assays, 43 (24.9%) were positive in only the FN-TG2-
IgA ELISA, and 5 (2.9%) patients were positive in the FN-TG2-IgG ELISA. 
The remaining 8 (4.6%) CD patients were negative in all of the the FN-TG2 
tests; four of them were younger than two years old. All CD patients positive in 
the FN-TG2-IgM ELISA also had positive values in the FN-TG2-IgA ELISA. 
The combined use of the FN-TG2 ELISAs for IgA and IgG antibodies resulted 
in 95.4% sensitivity and 99.0% specificity for childhood CD. Interestingly, the 
levels of anti-TG2 IgG were inversely associated with the age of the CD 
patients (p = 0.004, linear regression analysis), while no such association was 
observed for the anti-TG2 IgA and IgM antibodies. Unsuprisingly, the antibody 
levels of all the anti-TG2 antibody classes were positively associated with the 
degree of mucosal damage in the small intestine of CD patients (p < 0.01, 
Kruskal-Wallis test).  
 
 
5.3. Anti-TG2 autoantibodies: inhibition  
of TG2-heparin/HS interaction and  
the adhesion function of TG2 (Study III) 
Other than being an accurate serologic marker for CD, the role of anti-TG2 
antibodies in the disease pathogenesis has been less clearly defined, although 
various and even contradictory effects of anti-TG2 antibodies on the 
biochemical activity and cellular functions of TG2 have been described (Caputo 
et al. 2009; Lindfors et al. 2009). Relying on the recent findings on the role of 
TG2 in cell adhesion involving TG2 interactions with HS proteoglycans, we 
aimed to study whether anti-TG2 antibodies from CD patients’ sera could have 
an impact on the TG2-related cell adhesion function, by interfering with TG2 
binding to heparin/HS residues. The effects of sera and affinity purified anti-
TG2 antibodies on TG2 binding to immobilized heparin/HS and on Caco-2 
intestinal cell attachment to the FN-TG2 matrix were studied.  
 
Anti-TG2 autoantibodies inhibit TG2 binding to heparin/heparan sulphate 
The specificity of TG2 binding to immobilized heparin on a heparin binding plate 
was confirmed by applying different concentrations of TG2 to immobilized 
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heparin or to nonspecific glycosaminoglycan hyaluronic acid, and by competing 
TG2 binding with soluble heparin. Control experiments also demonstrated that 
the binding of monoclonal anti-TG2 (CUB 7402), used as the detection 
antibody for TG2, was not affected by anti-TG2 autoantibodies from CD 
patients (Figure 2 in Study III). 
When testing the serum effect on TG2 binding to immobilized heparin,  
sera from CD patients were divided into two groups based on anti-TG2 IgA 
levels: the CD1 group (anti-TG2 IgA  100 AU), and the CD2 group (anti-TG2 
IgA < 100 AU). The CD1 sera decreased TG2 binding to heparin (23 ± 13% of 
TG2 binding without sera) compared to the CD2 and the control sera (46 ± 17% 
and 51 ± 18%, respectively, p < 0.001; Figure 7A). Anti-TG2 IgA levels in sera 




Figure 7. The effect of human sera and affinity purified anti-TG2 antibodies on TG2 
binding to immobilized heparin. (A) Sera from CD patients with high anti-TG2 IgA 
levels (CD1) decreased TG2 binding to heparin compared to those with low antibody 
levels (CD2) and controls. (B) Negative correlation between anti-TG2 IgA values and 
inhibition of TG2 binding to heparin among CD sera. (C) Affinity purified anti-TG2 
antibodies from CD patients significantly inhibited TG2 binding to heparin as compared 
with controls, and (D) inhibition was inversely correlated with anti-TG2 IgA levels.  
* p < 0.05 
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(r = –0.72, p = 0.0003; Figure 7B). Similar results were obtained using HS 
instead of heparin in TG2 binding inhibition experiments. In line with the effect 
produced by the CD1 sera, affinity purified anti-TG2 antibodies inhibited TG2 
binding to heparin when comparing TG2 binding values after treatment with the 
CD1 samples (20 ± 8%), the CD2 samples (50 ± 18%), and the controls  
(73 ± 25%, p < 0.001; Figure 7C). There was also a high correlation between 
anti-TG2 IgA levels and the ability of samples to inhibit TG2 binding to heparin 
(r = –0.78, p = 0.003; Figure 7D). The concentration-dependent effect of human 
affinity purified anti-TG2 antibodies, but not rabbit anti-TG2 antibodies, on 
TG2 interactions with heparin and HS, was revealed when studying selected 
samples at different concentrations (Figure 4 in Study III). 
 
Anti-TG2 autoantibodies reduce TG2-dependent Caco-2 cell adhesion 
The finding that cell attachment to a FN coated surface can be reduced by RGD-
containing peptides, the potent inhibitors of integrin-mediated adhesion 
(Pierschbacher and Ruoslahti 1984), was also true in our experiments using the 
Caco-2 intestinal epithelial cell line. Similar to previous studies but using  
Caco-2 cells, we found that the RGD peptide inhibited cell adhesion to the  
FN-TG2 matrix less than to FN. The TG2-related cell adhesion pathway has 
been shown to complement the RGD-dependent adhesion process (Verderio et 
al. 2003; Telci et al. 2008), so we performed our antibody inhibition experi-
ments in the presence of the RGD peptide and normalized the results to the level 
obtained with the DGR control peptide with no effect on cell adhesion. Initially 
we found that treatment of the FN-TG2 coated surface with mouse monoclonal 
or rabbit polyclonal anti-TG2 antibodies had no significant effect on cell 
attachment compared with the normal IgG controls, but when the FN-TG2 
matrix was treated with CD patients’ sera, it resulted in lower Caco-2 cell 
attachment compared to the control sera (66  18% versus 97  14%, p < 0.05), 
and a similar difference persisted in the presence of the DGR control peptide 
(Figure 8A, 8B). The cell adhesion reducing effect was also obtained by using 
affinity purified antibodies: the incubation of the FN-TG2 surface with the CD1 
antibody samples decreased the Caco-2 attachment compared with the control 
samples (65  14% versus 86  22%, respectively, p < 0.05; Figure 8C). When 
affinity purified anti-TG2 antibodies were directly added to the cell suspension,  
no difference in the attachment assay was found between samples from CD 





Figure 8. Caco-2 cell attachment to the FN-TG2 coated surface treated with sera or 
anti-TG2 antibodies from CD patients. Treatment of FN-TG2 wells with CD patients’ 
sera containing high anti-TG2 (CD1) reduced Caco-2 cell attachment compared with the 
control sera both in the presence of DGR or RGD peptide, represented as (A) results of 
the attachment assay, (B) fluorescence images with stained actin filaments. (C) 
Attachment of Caco-2 cells to FN-TG2 was lower when treated with purified anti-TG2 
from CD1 sera as compared with the control samples. Bar, 20 m * p < 0.05 
 
Anti-TG2 autoantibodies have no effect on transamidase activity 
In order to investigate whether the cell attachment reducing effect of celiac 
patients’ anti-TG2 antibodies could be related to the change in the transami-
dation activity of TG2 bound to FN, the impact of affinity purified antibodies 
on the enzymatic activity of TG2 was studied using in vitro assay. Used as a 
positive control, mouse monoclonal CUB 7402 antibody inhibited the TG2 
activity down to the level of 13  2%. In the contrary, the affinity purified anti-
TG2 antibodies showed no effect on the transamidation activity of TG2 (activity 
93 ± 5% for CD1 and 94  5% for controls), with no correlation between TG2 




5.4. Heparin-binding peptides of TG2 (Study IV) 
Binding of TG2 and synthetic peptides to heparin by SPR 
SPR analysis was used to characterize the affinity of TG2 and its possible 
heparin-binding peptides to heparin, enabling the real-time monitoring of 
binding kinetics. High-affinity binding of TG2 to biotinylated heparin was 
detected by injecting different concentrations of TG2 over a sensor flow cell 
(Figure 9A). Using the Langmuir 1:1 binding model to fit sensorgram data, 
association and dissociation rate constants were obtained, resulting in an 
average dissociation constant of Kd = 34.7 nM for TG2. Of the four candidate 
heparin-binding TG2 peptides, P1 (202215) and P2 (261274) bound to 
heparin while the other two and a control peptide showed no detectable binding 
(Figure 9B). Kinetic analysis of P1 and P2 binding sensorgrams in different 
peptide concentrations revealed an average Kd = 12.7 M for P1and Kd = 3.7 M  
 
 
Figure 9. Binding of human recombinant TG2 and its peptides to immobilized heparin 
by SPR analysis. (A) Heparin binding sensorgrams of TG2 in the concentration range of 
5–67.5 nM, at a flow rate 20 l/min. (B) Binding of TG2 peptides P1–P5 to heparin at 
concentration 100 g/ml (54–78 nM) at flow rate 10 l/min. (C) Sequences 
corresponding to the heparin-binding peptides P1 (amino acids 202–215) and P2 (261–
274) in the structural model of TG2 (PDB code: 1KV3; PyMol software). Sequences 
corresponding to peptides are in red and marked with arrows. The N-terminal domain is 
shown in blue, the catalytic domain in green and the C-terminal β-barrel domains in 




for P2. The binding of TG2 and its peptides to immobilized heparin was 
completely abolished by an excess of soluble heparin, but not by hyaluronic 
acid. The sequences corresponding to the heparin-binding TG2 peptides P1 and 
P2 were localized within the structural model of TG2 as part of similarly 
oriented, alpha-helical structures, residing close to each other on the surface of 
the catalytic domain (Figure 9C). 
 
Immunoreactivity of heparin-binding TG2 peptides with CD patients’ IgA 
By testing CD patients’ sera IgA reactivity with TG2 peptides in ELISA, the 
peptides P1 and P2 were most immunoreactive compared to the other three TG2 
peptides (Figure 3 in Study IV; p < 0.001). A similar trend was observed for the 
control sera, but the CD sera had higher reactivity with all TG2 peptides, 
respectively (p < 0.01). There was no difference between CD and control 
patient serum IgA reactivity towards the enterovirus VP1 control peptide  
(p = 0.57). Serum IgA binding levels with different TG2 peptides were 
significantly correlated with each other (r = 0.66–0.93; p < 0.001) while no 
correlation existed between serum reactivity with any of the TG2 peptides and 
enterovirus VP1 peptide (r = 0.02–0.07; p > 0.7). 
 
Effect of TG2 peptides on Caco-2 cell attachment  
The effects of the TG2 peptides P1–P3, the enterovirus VP1 peptide, as well as 
the adhesion inhibiting RGD and non-inhibiting DGR control peptides, on 
Caco-2 cell attachment to FN and FN-TG2 coated surfaces were studied (Figure 
4 in Study IV). The RGD peptide inhibited cell attachment onto FN and FN-
TG2 surfaces compared to that of the DGR peptide, whereas inhibition was less 
effective on the FN-TG2 coated surface. In order to reduce the role of integrin-
mediated cell adhesion, the RGD peptide at 20 g/ml was included when 
studying the effect of the TG2 peptides on cell attachment. In these conditions, 
the TG2 peptide P2 reduced Caco-2 attachment to both the FN and FN-TG2 
coated surfaces compared with the enterovirus VP1 peptide or with only the 
RGD peptide. Surprisingly, the RGD-independent cell adhesion reducing effect 
of the TG2 peptide P2 was even more evident on the FN coated surface than on 




6.1. The role of anti-desmin IgA antibodies in CD 
In addition to the specific markers for CD – EmA-IgA and anti-TG2 IgA, a 
number of CD-associated autoantibodies have been described, although they are 
less sensitive and specific for the disease (Shaoul and Lerner 2007; Alaedini and 
Green 2008). The reported higher prevalence of SMA-IgA antibodies among 
CD patients led us to identify the main cytoskeletal targets of IgA antibodies in 
CD. It is known that cytoskeletal proteins, which constitute microfilaments and 
intermediate filaments, are the main antigens of SMA (Dighiero et al. 1990; 
Toh 1991). We identified desmin, by proteomic methods, as the cytoskeletal 
antigen recognised by serum IgA in about half of the CD patients. Similar 
results were obtained by using purified desmin in ELISA experiments, and an 
even higher prevalence of anti-desmin IgA (86.7%) was found in anti-TG2 IgA 
positive sera. 
One year before publishing our results, Clemente and colleagues reported on 
antibodies against filamentous actin, detected on HEp-2 cells, in the majority of 
CD patients (Clemente et al. 2000). Even though anti-actin reactivity was rare 
among our CD patients when tested by a western blot of HUC cytoskeletal 
proteins, we could not exclude the higher prevalence of anti-actin antibodies 
when tested by a different method. There are inherent differences between the 
methods such as IIF, WB and ELISA for autoantibody detection, concerning the 
complexity and the conformation of the antigen. Polymerized and filamentous, 
or unpolymerized and monomeric cytoskeletal proteins differ in their antigenic 
properties, which can explain, for example, the discrepancies between the IIF 
and ELISA results for anti-actin antibodies (Granito et al. 2004; Mackay et al. 
2008) and our finding of the higher anti-desmin IgA prevalence than  
uSMA-IgA in CD sera. Masking of the weaker uSMA-IgA staining by the 
prominent EmA-IgA reactivity when testing sera from CD patients, could also 
account for the lower uSMA-IgA prevalence. This is also supported by our 
results demonstrating that the affinity purified anti-desmin IgA produced a 
staining pattern resembling uSMA-IgA, whereas in the original serum only 
EmA-IgA was detectable. 
In the small intestinal mucosa of CD patients, desmin is coexpressed with  
α-smooth muscle actin in the lamina muscularis mucosa and in the smooth 
muscle strands traversing the lamina propria, and a similar distribution is 
observed in normal mucosa (Korhonen et al. 2000). Our finding, that anti-
desmin IgA antibodies were correlated with an anti-TG2 response, and that both 
antibodies decreased in response to a GFD in patients with CD, suggests that 
anti-desmin IgA is related to the disease process in the intestinal mucosa. The 
majority of CD patients in this study were graded as having subtotal villous 
atrophy of the small intestinal mucosa (Marsh IIIb), so we could not properly 
evaluate the association of anti-desmin IgA with the degree of tissue 
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destruction. While desmin is an intracellular protein, not accessible to 
antibodies in viable cells, we suggest that anti-desmin antibodies can be induced 
in response to tissue injury occurring in the inflammatory intestinal mucosa 
after a gliadin exposure. Indeed, molecular signatures on the dying cells have 
been demonstrated to become a target for autoantibodies (Gensler et al. 2001; 
Hansen et al. 2001), and rearranged cytoskeleton is also partially exposed on the 
surface of the apoptotic cells (Moisan and Girard 2006; Ndozangue-Touriguine 
et al. 2008). Bearing this in mind, the high reactivity of CD patients’ IgA 
antibodies with monomeric desmin in our study might be explained by antibody 
development against normally “hidden” epitopes when filamentous structures 
are disrupted. Interestingly, it has been shown that TG2 codistributes with 
stress-fibres in human vascular smooth muscle cells (Chowdhury et al. 1997), 
and with intermediate filaments in mouse dermal fibroblasts (Trejo-Skalli et al. 
1995). Furthermore, many cytoskeletal proteins, including desmin and actin, 
could act as transamidation substrates for TG2 as shown in vitro (Gard and 
Lazarides 1979; Huang et al. 1992), and in vivo in cells undergoing apoptosis 
(Nemes et al. 1997). Therefore, it is tempting to hypothesize that TG2 could 
modify the antigenic properties of desmin and other cytoskeletal proteins in the 
inflamed small intestinal mucosa of CD patients and thus contribute to the 
production autoantibodies. For example, in a different autoimmune disease, 
rheumatoid arthritis, the citrullination of arginine residues of another inter-
mediate protein, vimentin, induces a specific autoantibody response (Vossenaar 
et al. 2004). 
The role of IgA antibodies against desmin and other cytoskeletal proteins in 
the pathogenesis of CD has not been experimentally studied. Still, considering 
the increase in IgA anti-cytoskeletal antibodies in various gut inflammatory 
conditions (Mayet et al. 1990; Fabbro et al. 2008), anti-cytoskeletal antibody 
response is obviously not a finding specific for CD. Autoantibodies against 
cytoskeletal components, especially against intermediate filaments, have also 
been found among natural antibodies – the germline-encoded, preimmune and 
polyreactive type of antibodies (Lacroix-Desmazes et al. 1998; Thorpe et al. 
1998). The involvement of natural antibodies has been suggested in homeostatic 
functions like first line defence against pathogens, elimination of cell debris and 
immunoregulation (Lacroix-Desmazes et al. 1998; Lutz et al. 2009). Although 
differently regulated than the antigen-driven T-cell dependent antibody 
response, the transition of natural antibody specificities towards pathogenic 
autoantibodies can take place (Menge et al. 2002). 
The exact nature of anti-desmin IgA antibodies appearing in CD has not 
been explored in our study, but the specificity and gluten-dependence of these 
antibodies allows them to be considered as part of the complex immune 
response taking place in the small intestinal mucosa of CD patients. Based on 
our results, anti-desmin IgA detection is of no additional value for CD screening 
but its potential role as a supplemental marker for the integrity of the small 
intestinal mucosa needs further study. 
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6.2. Improved performance of a modified  
anti-TG2 ELISA for CD 
TG2 was identified as the main autoantigen in CD in 1997 (Dieterich et al. 
1997), and since then serum anti-TG2 antibodies have been utilized as useful 
diagnostic markers for CD. The second generation of anti-TG2 IgA immu-
noassays, using human antigen, have a diagnostic accuracy for CD comparable 
with the conventional EmA-IgA test (Sárdy et al. 1999; Sblattero et al. 2000; 
Lewis and Scott 2006). Anti-TG2 IgA antibodies have been shown to be highly 
sensitive and specific markers for CD while IgG and IgM class anti-TG2 
antibodies are less common in CD (Sblattero et al. 2000; Agardh et al. 2003; 
Feighery et al. 2003). However, the lower specificity of anti-TG2 IgA immu-
noassays compared with EmA-IgA has been observed, suggesting the need for 
further assay optimization. The major limitations of anti-TG2 antibody assays 
relate to the purity and proper conformation of the TG2 antigen, resulting in a 
fraction of false-positive or false-negative results (Carroccio et al. 2002; Sárdy 
et al. 2007). In order to overcome these analytical problems, we developed an 
ELISA using FN as a linker molecule to bind TG2 for detection of anti-TG2 
autoantibodies. The diagnostic accuracy of the modified ELISA for CD out-
performed that achieved by traditional ELISAs for anti-TG2 of all three major 
immunoglobulin classes (IgA, IgG, and IgM).  
Several methodological features could account for the better diagnostic 
performance of the FN-TG2 ELISA. First, the additional purification of TG2 by 
binding to its high affinity ligand FN could eliminate minor contaminant 
proteins with the ability to react with non-specific antibodies. Indeed, in our 
study, even after a two-step chromatographic purification of recombinant TG2 
minor protein impurities could still be detected. The role of additional FN 
“affinity” purification of TG2 is also supported by the striking difference 
between the FN-TG2-IgG and TG2-IgG assay results, as IgG is the main serum 
antibody fraction that is most sensitive to any protein impurities. The reduction 
of nonspecific reactivity enabled us to lower the cut-off values for the FN-TG2 
ELISAs without loss of specificity, and consequently to differentiate CD 
patients with “borderline” anti-TG2 antibody levels from the control group. The 
lower impact of the FN-TG2 ELISA on the anti-TG2 IgA assessment could be 
due to the high levels of anti-TG2 IgA antibodies in CD. 
A second explanation for the improved performance of the FN-TG2 ELISA 
comes from the finding that anti-TG2 antibodies from CD patients recognized 
TG2 bound to FN with asimilar extent than TG2 alone. This suggests that in the 
FN-TG2 complex the major TG2 epitopes remain accessible for antibody 
binding. Even more importantly, the FN bound TG2 resembles the extracellular 
appearance of TG2 in tissues, both on sections used for EmA detection, and in 
the jejunum of CD patients, where colocalisation of TG2 with the FN network 
has been demonstrated (Korponay-Szabó et al. 2000; Korponay-Szabó et al. 
2004). Therefore, it can be assumed that the FN-TG2 complex, mimicking the 
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in vivo state, and enabling the natural conformation and orientation of TG2 
molecules, serves as an appropriate antigen for anti-TG2 detection. 
We confirmed the high diagnostic sensitivity and specificity of anti-TG2 
IgA as a marker for untreated CD in a large cohort of children with CD and 
control subjects with normal intestinal histology. Anti-TG2 IgG antibodies 
which are less sensitive for CD, have been previously detected in about half of 
CD patients (Sblattero et al. 2000; Agardh et al. 2003), but they have been 
found to be a valuable marker for detecting CD patients with IgA-deficiency 
(Cataldo et al. 2000), and in a small subgroup of anti-TG2 IgA negative patients 
with normal IgA levels (Picarelli et al. 2001). Both aspects were consistent with 
our results, supporting the accepted view that combining the anti-TG2 IgA and 
IgG assays gives maximum diagnostic accuracy for CD screening. The finding 
that higher levels of anti-TG2 antibodies of the IgG class were detected in 
younger CD patients, but not of the IgA or IgM classes, could reflect the 
dynamics of antibody class switching during CD immunopathogenesis. In a 
previous prospective study anti-gliadin IgG antibodies have shown to emerge 
earlier than IgA antibodies during follow-up of children with a genetic risk for 
CD (Simell et al. 2007). 
Using the modified ELISA, we detected anti-TG2 IgM antibodies in half of 
the CD patients, which is a considerably higher prevalence than reported 
previously (Agardh et al. 2003; Feighery et al. 2003). The better diagnostic 
performance of the FN-TG2-IgM ELISA could be the main reason for the 
difference, as the positivity rate obtained with the traditional ELISA in our 
study was similar to that in a previous report (Feighery et al. 2003). Our results 
show that the assessment of anti-TG2 IgM had no additional diagnostic value 
for the serological screening of childhood CD. Still, possible associations with 
disease duration or other clinical parameters cannot be ruled out for anti-TG2 
IgM and this should be addressed in further studies. An established ELISA, 
based on recombinant TG2 bound to FN, is suggested for the assessment of 
anti-TG2 IgA and IgG antibodies in childhood CD screening as the format is 
relatively simple, reliable, and, most importantly, has better diagnostic 
performance than using the same antigen without FN. The novel ELISA could 
be useful for the screening of disease groups with a reported higher prevalence 
of anti-TG2 antibodies, and where the presence of false positive results could 
come into question. 
 
 
6.3. The functional effects of anti-TG2 autoantibodies 
A number of studies have described the effects of anti-TG2 autoantibodies on 
the transamidase activity of TG2, and on various cellular functions in vitro, but 
despite this there is still no consensus on the role of anti-TG2 antibodies in the 
immunopathogenesis of CD. Also, not much is known about the mechanisms 
how anti-TG2 autoantibodies exert their effects on cell behaviour. Our 
15 
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hypothesis-driven approach revealed that anti-TG2 antibodies from CD patients 
could interfere with the cell adhesion function of TG2. This was substantiated 
by the inhibiting effect of CD patients’ autoantibodies on TG2 binding to 
heparin/HS, as well as on the RGD-independent attachment of Caco-2 intestinal 
epithelial cells onto the FN-TG2 matrix. Moreover, heparin-binding peptides of 
TG2 displayed increased immunoreactivity with the serum IgA of CD patients. 
It is most likely that the inhibitory effect of anti-TG2 autoantibodies on TG2 
binding to heparin/HS can be explained by antibody blocking of the TG2 
regions responsible for interactions with heparin/HS. We began to define the 
heparin-binding sites of TG2 by using synthetic candidate peptides in heparin 
binding studies, revealing two heparin-binding candidate regions, corresponding 
to amino acids 202–215 and 261–274 in the core domain of TG2. The sequence 
261–274 contains the typical heparin-binding consensus sequence XBBXBX 
(B-basic, X-non-basic amino acid) and both regions are part of alpha-helical 
structures, residing close to each other on the surface of the molecule. The high 
content of positively charged amino acid residues in these structures in a 
generally acidic TG2 molecule could allow the binding of negatively charged 
HS residues. Similar to our findings, Wang and colleagues recently 
demonstrated that TG2 amino acids 202 – 222 form the major heparin-binding 
site of TG2 by using molecular modelling, site-directed mutagenesis and corres-
ponding peptide analysis (Wang et al. 2012). Previous studies show no signi-
ficant effect of heparin binding on the transamidase activity of TG2 (Gambetti 
et al. 2005; Scarpellini et al. 2009), suggesting that heparin binding does not 
affect substrate recognition in the catalytic site. It has also been demonstrated 
earlier, that antibodies could react with protein heparin-binding sites (Opper-
mann et al. 2006; Inagaki et al. 2011), for example, the peptides of laminin 111 
with heparin and syndecan-4 binding activity were predominantly recognized 
by serum antibodies from patients with endometriosis (Inagaki et al. 2011). The 
recently identified main conformational epitope of CD anti-TG2 antibodies also 
contains arginine residue which is critical for antibody binding (Simon-Vecsei 
et al. 2012). Therefore, the surface exposition and higher content of charged 
amino acids could form the structural basis for the higher immunogenicity of 
the protein heparin-binding regions. 
Syndecan-4 has been demonstrated as the candidate HSPG for binding TG2 
(Scarpellini et al. 2009), and has been suggested as being involved in the RGD-
independent adhesion process (Verderio et al. 2003; Telci et al. 2008). We have 
not addressed interaction between TG2 and syndecan-4 in our studies. Still, 
reduced cell attachment on the anti-TG2 autoantibody treated FN-TG2 matrix 
provides indirect evidence that the adhesion function of TG2, related to the 
binding of cell surface proteoglycans, could be compromised by autoantibodies. 
The finding that the TG2 peptide 261–274 decreased cell attachment on the 
surfaces of both FN and FN-TG2, could also be explained by the inhibition of 
interactions between cell surface HSPGs and heparin-binding sites in FN and 
TG2. Our results suggest that the effect of anti-TG2 autoantibodies on the 
59 
intestinal epithelial cell attachment is related to targeting extracellular TG2 
bound to the FN matrix, rather than to TG2 expressed on the cell surface. The 
improved performance of our FN-TG2 ELISA also supports the preferred 
binding of autoantibodies to the FN bound TG2, and most probably, extra-
cellular TG2 is the primary target of CD patients’ autoantibodies in the small 
intestinal mucosa (Korponay-Szabó et al. 2004).  
Questions may arise as to whether anti-TG2 autoantibodies could interfere 
with FN binding to TG2 as there are mouse monoclonal antibodies available 
that demonstrate this (Akimov and Belkin 2001b). Also, in a recent work serum 
anti-TG2 autoantibody reactivity decreased when TG2 was linked to FN 
(Sóñora et al. 2011). In opposite to this, in our ELISA studies we have not seen 
the difference between autoantibody binding to TG2 directly coated on plastic 
and when bound to FN. In another study it has been suggested that, although 
anti-TG2 autoantibodies can form complexes with TG2 and FN in blood 
circulation, they do not seem to disrupt the FN-TG2 interaction (Lorand and 
Graham 2003).   
Anti-TG2 autoantibodies had no effect on the transamidase activity of FN 
bound TG2, and therefore this mechanism is unlikely to be responsible for the 
reduced cell attachment in our studies. Although the protein cross-linking 
function of TG2 plays a role in cell-ECM interactions (Zemskov et al. 2006), 
the adhesion promoting effect of TG2 has been shown to be independent of 
TG2 transamidase activity (Akimov et al. 2000; Verderio et al. 2003). The 
variable effects of anti-TG2 autoantibodies on the transamidase activity of TG2 
obtained so far could be due to differences in the methods and antibody samples 
used for testing TG2 activity.  
Previous studies show that the IgA fraction or anti-TG2 antibodies from CD 
patients inhibits intestinal epithelial cell differentiation (Halttunen and Mäki 
1999) and endocytosis (Caputo et al. 2010), promotes cell proliferation (Barone 
et al. 2007a), disturbs angiogenesis (Myrsky et al. 2008), and increases intesti-
nal and endothelial cell permeability (Zanoni et al. 2006; Myrsky et al. 2009). 
These findings are explained either by the anti-TG2 antibody effects on 
transamidase activity (Myrsky et al. 2009) or the nonenzymatic functions of 
TG2 (Barone et al. 2007a). The mechanisms by which anti-TG2 autoantibodies 
could cause these phenomena are of interest, as is the possible contribution of 
the mechanism proposed by us – antibodies interfering with TG2 binding to cell 
surface HSPGs and the related cell adhesion function. The involvement of anti-
TG2 antibodies in modifying cellular adhesion was also revealed by the recent 
finding, that IgG purified from CD patients’ sera impaired the invasiveness of 
trophoblastic cells (Di Simone et al. 2010).  
The question remains as to whether the proposed inhibitory mechanism of 
CD autoantibodies on the TG2 and heparin/HS interaction and on cell adhesion 
could have implications for the immunopathogenesis and tissue remodelling of 
small intestinal lesions in CD. TG2-related cell adhesion may play a particular 
role in cell survival in the inflamed tissues where the RGD-dependent adhesion 
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is impaired (Verderio et al. 2003). Based on this, we suggest that binding of 
anti-TG2 antibodies to extracellular TG2 and hindering its interactions with cell 
HSPGs could lead to the loosening of adhesion contacts between epithelial cells 
and the basement membrane in the small intestinal mucosa of CD patients 
(Figure 10). Indeed, blistering of the epithelial cells in the small intestinal 
lesions of CD patients has been previously reported (Kainulainen et al. 2002). 
Further studies are needed, using human biopsy cultures or suitable disease 
models, in order to explore the possible role of TG2-mediated cell adhesion 
pathways and anti-TG2 antibodies in the pathogenesis of CD. Selection and 
cloning of antibodies from the target tissue, the tool successfully used for 
dissecting the anti-TG2 antibody response (Marzari et al. 2001; Di Niro et al. 
2012), could lead to more detailed characterization of the nature and role of 




Figure 10. Schematic model of the inhibitory mechanism of anti-TG2 autoantibodies on 
cell adhesion in CD. (A) In a normal situation, cell adhesion is mediated by interactions 
of cell surface integrins and HSPGs (syndecan-4) with FN-TG2 matrix outside the cell. 
(B) In an inflamed tissue like in CD, the RGD-dependent adhesion is suppressed by 
short RGD peptides, and TG2 binding to HS chains of syndecan-4 is inhibited by anti-






1. Desmin was identified as the most frequently recognized cytoskeletal 
antigen by serum IgA of children with CD, detected in more than half of 
patients. Anti-desmin IgA antibodies were not cross-reactive with TG2, and 
both anti-desmin and anti-TG2 IgA levels decreased in response to a gluten 
free diet. Anti-desmin antibodies could be induced in response to ongoing 
intestinal tissue destruction as part of the complex immune activation in CD. 
2. The diagnostic performance of the modified ELISA, using FN bound TG2, 
was superior to the conventional ELISA for anti-TG2 IgA, IgG and IgM 
detection in children with CD. The combined use of an anti-TG2 IgA and 
IgG ELISA resulted in 95.4% sensitivity and 99.0% specificity for 
childhood CD, whereas anti-TG2 IgM detection had no additional value for 
CD screening. The purification effect of binding TG2 to its ligand FN, as 
well as the oriented conformation mimicking the situation in vivo, could be 
the main reasons for the superior accuracy of the modified ELISA for anti-
TG2 detection. The novel ELISA could be useful for screening for 
childhood CD with high diagnostic accuracy. 
3. Anti-TG2 antibodies from the sera of CD patients inhibited TG2 binding to 
heparin/HS in a concentration-dependent manner. The treatment of the FN-
TG2 surface with anti-TG2 antibodies from CD sera reduced RGD-
independent intestinal epithelial cell attachment. Anti-TG2 autoantibodies 
had no effect on the transamidase activity of TG2 in vitro. Our results 
suggest that anti-TG2 autoantibodies from CD patients affect the cell 
adhesion function of TG2. We hypothesize that the binding of anti-TG2 
antibodies to extracellular TG2 and hindering its interactions with cell 
HSPGs can lead to the loosening of adhesion contacts between epithelial 
cells and the basement membrane in the small intestinal mucosa of CD 
patients. 
4. Two heparin-binding TG2 sequences, consisting of amino acid residues 
202–215 and 261–274, were identified by analysing corresponding peptides 
in SPR biosensor studies. Heparin-binding TG2 peptides were immuno-
reactive with serum IgA of CD patients, and the TG2 peptide P2 (261–274) 
reduced intestinal epithelial cell adhesion on surfaces coated either with FN 
or FN-TG2. Identified heparin-binding sequences reside close to each other 
on the surface of the TG2 core domain and these regions could be involved 
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SUMMARY IN ESTONIAN 
Autoantikehad desmiini ja transglutaminaas 2 vastu tsöliaakia 
korral: diagnostiline ja funktsionaalne tähendus 
Tsöliaakia on krooniline peensoolehaigus, mille vallandavad nisus leiduvad 
gluteeni valgud, ning sarnased valgud rukkis ja odras. Tsöliaakia korral on 
häirunud normaalne immuuntolerantsus vastavate teraviljavalkude suhtes, mis 
viib immuunvastuse ja põletiku tekkeni peensoole limaskestas ning soole-
hattude kahjustumiseni. Peamised tsöliaakia kliinilised sümptomid, mida kirjel-
dati juba 19. saj. lõpus, on toitainete maladsorptsioonist tingitud kõhulahtisus, 
kõhupuhitus ja kasvu peetumine lastel. Pikka aega ongi tsöliaakiat peetud suhte-
liselt harvaesinevaks väikelaste haiguseks, mis tekib kui lapsed hakkavad 
sööma teraviljajahust toite ja avaldub kirjeldatud „klassikaliste” sümptomitega. 
Viimasel paaril aastakümnel on tsöliaakia muutunud sagedaseks haiguseks, 
millel on lai kliiniline spekter – alates „klassikalisest” kuni atüüpiliste ja sub-
kliiniliste avaldumisvormideni. Kõrge levimuse, milleks on kuni 1% arenenud 
maade elanikkonnast, üheks põhjuseks on efektiivsete sõeluuringumeetodite 
kasutuselevõtt, teisalt on tegemist elukeskkonna muutustest tingitud levimuse 
tõusuga, mis on omane paljudele autoimmuunhaigustele. 
Tsöliaakia patogeneesis on kesksel kohal loomulik ja adaptiivne immuun-
vastus gluteeni peptiidide vastu. Haigusel on ka oluline pärilik komponent ning 
tugevaim seos on HLA II klassi heterodimeere DQ2 ja DQ8 kodeerivate alleeli-
dega, esinedes pea kõigil patsientidel. Tsöliaakiahaigete peensoole limaskestas 
esitletakse gluteeni peptiide DQ2/DQ8 vahendusel CD4+ T-rakkudele, mis 
produtseerivad põletikutsütokiine ja aktiveerivad omakorda teisi rakke. Teise 
järjestusega gluteeni peptiidid tekitavad stressireaktsiooni soole epiteel-
rakkudes, mis viib intraepiteliaalsete CD8+ T-rakkude aktivatsioonile ja epiteel-
rakkude hävitamisele. Immuunkahjustuse mehhanismide tulemusena kujuneb 
välja soolehattude atroofia, krüptide hüperplaasia ja soole läbilaskvuse suurene-
mine. Kõik need muutused taanduvad täieliku gluteenivaba dieedi pidamisel, 
mis ongi tsöliaakia ainsaks efektiivseks raviks. 
Lisaks gluteenivastastele immuunreaktsioonidele tekivad tsöliaakiahaigetel 
autoantikehad transglutaminaas 2 (TG2) ja teiste autoantigeenide vastu. TG2 on 
multifunktsionaalne valk, mis omab transamideerivat aktiivsust ning osaleb 
protsessides nagu rakkude proliferatsioon, apoptoos, adhesioon, endotsütoos ja 
rakuvälise maatriksi kujunemine. Tsöliaakiahaigete peensooles on TG2 ekspres-
sioon tõusnud ning TG2 poolt modifitseeritud gluteeni peptiidid võimendavad 
täiendavalt T-rakkude vastust. Samuti võib TG2 siduda gluteeni peptiide 
kovalentselt iseenda külge ja selliste komplekside teket peetakse oluliseks anti-
TG2 antikehade indutseerimisel. Seerumi IgA tüüpi anti-TG2 antikehad on 
kujunenud tsöliaakia tundlikuks ja spetsiifiliseks haigusmarkeriks, mida määra-
takse haiguskahtluse või -riski korral. Vaatamata anti-TG2 IgA kõrgele haigus-
spetsiifilisusele, leitakse teatud haigusgruppides vähesel arvul valepositiivseid 
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tulemusi. Kuna peensoole biopsia teostamine on nõutav tsöliaakia diagnoosi-
miseks, siis on oluline võimalikult efektiivne patsientide eelnev selektsioon 
biomarkerite alusel. Seega, jätkuv anti-TG2 antikehade testide arendamine on 
vajalik parema diagnostilise võimekuse saavutamiseks. Samuti on vajadus 
täiendavate haigusseoseliste biomarkerite järele seerumis, mis võimaldaksid 
hinnata koekahjustuse ulatust peensoole limaskestas. Lisaks kasutusele bio-
markerina, on võimalik ka anti-TG2 antikehade osalemine tsöliaakia immuno-
patogeneesis. Anti-TG2 IgA antikehi produtseeritakse tsöliaakiahaigete peen-
soole limaskestas ja nad kolokaliseeruvad rakuvälise TG2-ga basaalmembraani 
all. In vitro katsetes on näidatud, et tsöliaakiahaigete anti-TG2 antikehad 
mõjutavad TG2 transamideerivat aktiivsust ja mitmesuguseid TG2 rakulisi 
funktsioone, kuid täpsemad antikehade toimemehhanismid pole teada.  
 
Käesolevas väitekirjas seatud eesmärkideks oli: 
 iseloomustada tsütoskeleti valkude vastaste antikehade esinemist tsöliaakia-
haigete laste vereseerumis ja identifitseerida peamised autoantigeenid;  
 võrrelda uudse ensüümseoselise immunosorbentmeetodi (ELISA) diagnosti-
list võimekust senise ELISA testiga anti-TG2 antikehade määramiseks 
tsöliaakiahaigete laste seerumis; 
 hinnata tsöliaakiahaigete anti-TG2 antikehade mõju TG2 seondumisele 
hepariini/heparaansulfaadiga ja rakkude TG2-sõltuvale adhesioonile; 
 määratleda peamised hepariiniga seonduvad TG2 piirkonnad, kasutades 
kandidaatpeptiide seondumis- ja funktsionaalsetes katsetes. 
 
Leidsime, et tsütoskeleti valkude hulgast reageeris tsöliaakiahaigete seerumi 
IgA kõige sagedamini desmiiniga, mis on lihasspetsiifiline vahepealsete fila-
mentide hulka kuuluv valk. Desmiinivastaseid IgA antikehi leiti enam kui 
pooltel tsöliaakiahaigetest lastest nii immunoblotanalüüsil kui ELISA meeto-
diga. Desmiinivastane IgA ei ristreageerinud TG2-ga, kuid mõlemate anti-
kehade tase langes gluteenivaba dieedi toimel. Antikehade teke desmiini vastu 
võib olla vastuseks juba kujunenud koekahjustusele tsöliaakiahaigete peen-
sooles. Desmiinivastaste IgA antikehade kasutus koekahjustuse markerina 
tsöliaakia korral vajab täiendavat uurimist. 
Meie poolt välja töötatud uudne ELISA test, mis põhineb TG2 seondumisel 
tema ligandi fibronektiini (FN) külge (FN-TG2 ELISA), oli parema diagnosti-
lise võimekusega võrreldes senise testiga nii IgA, IgG kui ka IgM tüüpi anti-
TG2 antikehade määramiseks tsöliaakiahaigete laste seerumis. Kombineeritud 
IgA ja IgG tüüpi anti-TG2 antikehade määramisel saavutati diagnostiline 
tundlikkus 95.4% ja spetsiifilisus 99.0%. Autorite arvates on modifitseeritud 
ELISA parem diagnostiline võimekus seotud nii TG2 täiendava puhastamisega 
seondumisel FN-ga kui ka seondunud TG2 konformatsiooniga, mis jäljendab 
olukorda in vivo. 
Kõrge anti-TG2 antikehade tasemega tsöliaakiahaigete seerumid ja 
afiinsuspuhastatud anti-TG2 antikehad inhibeerisid TG2 seondumist hepariini ja 
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heparaansulfaadiga (HS) kontsentratsioonist sõltuvalt. Kuna TG2 seondumine 
HS jääkidega on seotud TG2 adhesioonifunktsiooniga, uurisime anti-TG2 auto-
antikehade mõju soole epiteelrakkude adhesioonile. FN-TG2 kompleksiga 
kaetud pinna mõjutamisel anti-TG2 autoantikehadega vähenes soole epiteel-
rakkude kinnitumine, mis oli sõltumatu integriinide ja RGD motiivi vahendatud 
adhesioonist. Uurides võimalikele hepariiniga seonduvatele TG2 järjestustele 
vastavaid sünteetilisi peptiide, leidsime et aminohapetele 202–215 ja 261–274 
vastavad peptiidid seonduvad hepariiniga biosensoranalüüsil. Samad peptiidid 
olid immunoreaktiivsed tsöliaakiahaigete seerumi IgA-ga ning peptiid 261–274 
vähendas sooleepiteelrakkude kinnitumist FN-TG2 kaetud pinnal. Leitud 
hepariinseonduvad järjestused paiknevad lähestikku TG2 pinnal ja need võivad 
olla olulised TG2 seondumisel rakupinna HS-proteoglükaanidega.  
Lähtudes saadud tulemustest püstitasime uudse hüpoteesi, et tsöliaakia-
haigete anti-TG2 antikehad, seondudes rakuvälise TG2-ga peensoole limas-
kestas ja takistades TG2 seondumist rakupinna HS-proteoglükaanidega, nõrgen-
davad soole epiteelrakkude adhesioonikontakte rakuvälise maatriksiga ning 
võivad seeläbi osaleda tsöliaakia koekahjustuse tekkel. 
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